

CITATION REPORT

List of articles citing

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

DOI: 10.1016/j.cell.2020.02.058
Cell, 2020, 181, 281-292.e6.

Source: <https://exaly.com/paper-pdf/76958749/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2281	COVID-19 Outbreak: An Overview. 2019 , 64, 215-223		128
2280	Genetics of Severe Acute Respiratory Syndrome Coronavirus-2 and Diagnosis of Coronavirus Disease-2019: An Overview. 2020 , 22, 236-247		0
2279	How COVID-19 induces cytokine storm with high mortality. 2020 , 40, 37		238
2278	In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. 2020 , 15, e0240149		31
2277	Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. 2020 , 11, 552909		136
2276	Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution. 2020 , 11, 2112		18
2275	Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. 2020 , 7, 226		8
2274	High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. 2021 , 74, 796-803		12
2273	Drug Weaponry to Fight Against SARS-CoV-2. 2020 , 7, 204		2
2272	Endothelial Cell Contributions to COVID-19. 2020 , 9,		12
2271	Recent Perspectives on COVID-19 and Computer-Aided Virtual Screening of Natural Compounds for the Development of Therapeutic Agents Towards SARS-CoV-2. 2020 , 433		1
2270	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. 2020 , 18, 2100-2106		4
2269	Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment. 2020 , 6, e05278		15
2268	Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain. 2020 , 21, 100451		11
2267	Immunotherapeutic approaches to curtail COVID-19. 2020 , 88, 106924		29
2266	The current situation of COVID-19 in Sudan. 2020 , 37, 100746		13
2265	Comprehensive Analysis of the Glycan Complement of SARS-CoV-2 Spike Proteins Using Signature Ions-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation (ETHcD) Mass Spectrometry. 2020 , 92, 14730-14739		29

2264	The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. 2020 , 10, 16944	50
2263	Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. 2020 , 1-17	8
2262	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. 2020 , 13, 255-260	12
2261	Sex steroids skew ACE2 expression in human airway: a contributing factor to sex differences in COVID-19?. 2020 , 319, L843-L847	23
2260	Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis. 2020 , 15, e0240577	17
2259	Syncytia formation by SARS-CoV-2-infected cells. 2020 , 39, e106267	167
2258	Bibliometric and Visualization Analysis of Human Coronaviruses: Prospects and Implications for COVID-19 Research. 2020 , 10, 581404	16
2257	Pathophysiology of Cardiovascular Complications in COVID-19. 2020 , 11, 575600	21
2256	Is There a Link between Bisphenol A (BPA), a Key Endocrine Disruptor, and the Risk for SARS-CoV-2 Infection and Severe COVID-19?. 2020 , 9,	8
2255	Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients. 2020 , 16, 3028-3036	8
2254	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. 2020 , 35, 857-860	17
2253	Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar. 2020 , 76, 2024-2035	21
2252	Low-Cost, Large-Scale Production of the Anti-viral Lectin Griffithsin. 2020 , 8, 1020	12
2251	ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. 2020 , 11, 576745	98
2250	New SARS-CoV-2 Infection Detected in an Italian Pet Cat by RT-qPCR from Deep Pharyngeal Swab. 2020 , 9,	25
2249	Co-expression of peripheral olfactory receptors with SARS-CoV-2 infection mediators: Potential implications beyond loss of smell as a COVID-19 symptom. 2020 , 46, 949-956	24
2248	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. 2020 , 182, 114225	40
2247	Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects. 2020 , 131, 110748	14

2246	Cryo-EM as a powerful tool for drug discovery. 2020 , 30, 127524	19
2245	Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test. 2020 , 2, 226-231	33
2244	Clinical performance of a semi-quantitative assay for SARS-CoV2 IgG and SARS-CoV2 IgM antibodies. 2020 , 510, 790-795	6
2243	Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. <i>Cell</i> , 2020 , 183, 739-751, e8	566
2242	On the genetics and immunopathogenesis of COVID-19. 2020 , 220, 108591	22
2241	Repurposing anticancer drugs for the management of COVID-19. 2020 , 141, 40-61	30
2240	Biosensor and molecular-based methods for the detection of human coronaviruses: A review. 2020 , 54, 101662	22
2239	COVID-19 Vaccine: A comprehensive status report. 2020 , 288, 198114	380
2238	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. 2020 , 50, 1313-1324	41
2237	Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations. 2020 , 5,	17
2236	ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. 2020 , 131, 110678	98
2235	Druggable targets from coronaviruses for designing new antiviral drugs. 2020 , 28, 115745	10
2234	Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity. 2020 , 18, 2573-2582	26
2233	Cardiac inflammation in COVID-19: Lessons from heart failure. 2020 , 260, 118482	40
2232	The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydrate-carbohydrate interactions. 2020 , 144, 110155	30
2231	Thermodynamic equilibrium dose-response models for MERS-CoV infection reveal a potential protective role of human lung mucus but not for SARS-CoV-2. 2020 , 16, 100140	12
2230	Structural and functional modelling of SARS-CoV-2 entry in animal models. 2020 , 10, 15917	37
2229	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 2020 , 370,	289

2228	ACEIs and ARBs and Their Correlation with COVID-19: A Review. 2020 , 13, 3217-3224		15
2227	What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses. 2020 , 11, 2147		78
2226	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. 2020 , 11, 2016		10
2225	Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses. 2020 , 54, 102350		38
2224	Machine learning methods accurately predict host specificity of coronaviruses based on spike sequences alone. 2020 , 533, 553-558		11
2223	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020 , 183, 1024-1042.e21	56.2	601
2222	A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors. 2020 , 32, 108175		118
2221	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. 2021 , 8, 385-400		18
2220	Identification of twenty-five mutations in surface glycoprotein (Spike) of SARS-CoV-2 among Indian isolates and their impact on protein dynamics. 2020 , 21, 100891		10
2219	Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14. 2020 , 144, 110168		7
2218	Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients. 2020 , 144, 110271		29
2217	Nanomedicine strategies to target coronavirus. 2020 , 35, 100961		28
2216	Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases. 2020 , 7, 1868-1878		22
2215	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. 2020 , 12,		17
2214	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. 2020 , 887, 173568		2
2213	Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics. 2020 , 56, 106177		17
2212	In-silico design of a potential inhibitor of SARS-CoV-2 S protein. 2020 , 15, e0240004		25
2211	All Surfaces Are Not Equal in Contact Transmission of SARS-CoV-2. 2020 , 3, 1433-1441		24

2210 Potential Therapeutic Options for COVID-19. **2020**, 2, 89-95

2209 Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. **2020**, 370, 1089-1094 153

2208 A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell*, **2020**, 183, 1058-1069.e19 56.2 182

2207 Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19. **2020**, 110, 101874 10

2206 Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. **2020**, 1, 100126 134

2205 Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. **2020**, 9, 2433-2445 86

2204 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. **2020**, 370, 856-860 809

2203 Neuropilin-1 is a host factor for SARS-CoV-2 infection. **2020**, 370, 861-865 568

2202 Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection. **2020**, 40, 39 24

2201 A comprehensive review about SARS-CoV-2. **2020**, 15, 625-648 37

2200 The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection. **2020**, 10, 550571 14

2199 As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention. **2020**, 11, 591897 6

2198 Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. **2020**, 50, 2025-2040 111

2197 An immunoinformatics study on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates. **2020**, 6, e04865 5

2196 2020 update on human coronaviruses: One health, one world. **2020**, 8, 100043 12

2195 Potential of graphene-based materials to combat COVID-19: properties, perspectives, and prospects. **2020**, 18, 100385 53

2194 Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. **2020**, 27, 905-919.e10 92

2193 Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. **2020**, 10, 17699 96

2192	Gamut of cardiac manifestations and complications of COVID-19: a contemporary review. 2020 , 68, 1334-1340	9
2191	Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. 2020 , 13, 1178633720962935	16
2190	The Role of the Ocular Tissue in SARS-CoV-2 Transmission. 2020 , 14, 3017-3024	12
2189	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. 2020 , 33, 108322	35
2188	Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications. 2021 , 7, 1441-1451	32
2187	Targeting Proteases for Treating COVID-19. 2020 , 19, 4316-4326	36
2186	Engineered ACE2 receptor traps potentially neutralize SARS-CoV-2. 2020 , 117, 28046-28055	110
2185	Exploring the Role of Endothelial Cell Resilience in Cardiovascular Health and Disease. 2021 , 41, 179-185	9
2184	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. 2020 , 33, 108274	107
2183	An aberrant STAT pathway is central to COVID-19. 2020 , 27, 3209-3225	95
2182	The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms. 2020 , 1-9	11
2181	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. 2020 , 75, 458-466	19
2180	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. 2020 , 104, 104326	12
2179	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. 2020 , 33, 108254	107
2178	Furin: A Potential Therapeutic Target for COVID-19. 2020 , 23, 101642	86
2177	Structure of the Pandemic. 2020 , 28, 874-878	3
2176	Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. 2020 , 1-10	7
2175	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. 2020 , 99, 1953-1965	27

2174	Topoisomerase III- β s required for efficient replication of positive-sense RNA viruses. 2020 , 182, 104874	9
2173	Benefits and limitations of serological assays in COVID-19 infection. 2020 , 67, S163-S166	20
2172	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. 2020 , 5, 91	153
2171	Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. 2020 , 11, 582870	22
2170	Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein. 2020 , 4, 100038	13
2169	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
2168	Molecular Docking and ADMET Study of Bioactive Compounds of Against Main Protease of SARS-CoV2. 2020 , 49, 2999-2999	21
2167	Reducing False Negatives in COVID-19 Testing by Using Microneedle-Based Oropharyngeal Swabs. 2020 , 3, 1589-1600	20
2166	Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. 2020 , 6,	44
2165	GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. 2020 , 132, 110816	7
2164	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008	39
2163	Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19. 2020 , 21, 100438	8
2162	Virus-, host-, immune-based targets for COVID-19 therapy. 2020 , 25, 2071-2073	1
2161	Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach. 2020 , 320, 114493	46
2160	Association of smoking status with outcomes in hospitalised patients with COVID-19. 2020 , 7,	11
2159	Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. 2020 , 319, H1059-H1068	13
2158	Clinical Features of COVID-19 Patients with Different Outcomes in Wuhan: A Retrospective Observational Study. 2020 , 2020, 2138387	14
2157	Interpreting, analysing and modelling COVID-19 mortality data. 2020 , 101, 1-26	18

2156	The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. 2020 , 182, 114215	28
2155	Update on serologic testing in COVID-19. 2020 , 510, 746-750	16
2154	Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. 2020 , 885, 173496	9
2153	Control of systemic inflammation through early nitric oxide supplementation with nitric oxide releasing nanoparticles. 2020 , 161, 15-22	4
2152	Molecular biology of coronaviruses: current knowledge. 2020 , 6, e04743	40
2151	Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. 2020 , 53, 487-495	73
2150	Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. 2020 , 259, 118275	44
2149	ABO blood group system is associated with COVID-19 mortality: An epidemiological investigation in the Indian population. 2020 , 27, 253-258	26
2148	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. 2020 , 288, 198141	59
2147	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. 2020 , 1, 100099	40
2146	Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. 2020 , 19, 4587-4608	26
2145	Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic. 2020 , 5, 222	5
2144	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. 2020 , 117, 25254-25262	116
2143	Correlation analysis of coagulation dysfunction and liver damage in patients with novel coronavirus pneumonia: a single-center, retrospective, observational study. 2020 , 125, 293-296	8
2142	Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. 2020 , 1-24	9
2141	In silico exploration of small-molecule β helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2. 2020 , 1-12	3
2140	Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells. 2020 , 9, 2169-2179	21
2139	COVID-19 pandemic preparedness: A practical guide from clinical pharmacists' perspective. 2020 , 77, 1510-1515	2

2138	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. 2020 , 17, 543-558	560
2137	An -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. 2020 , 12,	96
2136	COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Soci��t�� d'Andrologie de langue Fran��aise SALF). 2020 , 30, 10	11
2135	Oncology-Inspired Treatment Options for COVID-19. 2020 , 61, 1720-1723	11
2134	Atomistic simulation reveals structural mechanisms underlying D614G spike glycoprotein-enhanced fitness in SARS-COV-2. 2020 , 41, 2158-2161	30
2133	SARS-CoV-2-Encoded Proteome and Human Genetics: From Interaction-Based to Ribosomal Biology Impact on Disease and Risk Processes. 2020 , 19, 4275-4290	9
2132	Targeting virus-host interaction by novel pyrimidine derivative: an approach towards discovery of potential drug against COVID-19. 2021 , 39, 5768-5778	17
2131	Distinct conformational states of SARS-CoV-2 spike protein. 2020 , 369, 1586-1592	552
2130	Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. 2020 , 319, C500-C509	4
2129	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. 2020 , 15, 359-386	199
2128	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
2127	Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an study for drug development. 2021 , 39, 6306-6316	94
2126	Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist. 2020 , 2, e0154	12
2125	SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. 2020 , 11, 3581	158
2124	Immune-mediated approaches against COVID-19. 2020 , 15, 630-645	178
2123	The molecular virology of coronaviruses. 2020 , 295, 12910-12934	175
2122	Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?. 2020 , 55, 917-919	1
2121	Design of engineered surfaces for prospective detection of SARS-CoV-2 using quartz crystal microbalance-based techniques. 2020 , 17, 425-432	27

2120	The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. 2020 , 296, 205-219	99
2119	SARS-CoV-2 surveillance for a non-human primate breeding research facility. 2020 , 49, 322-331	8
2118	Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. 2020 , 94,	89
2117	Minireview of progress in the structural study of SARS-CoV-2 proteins. 2020 , 1, 53-61	23
2116	Recombinant protein targeting and opsonizing spike glycoprotein for enhancing SARS-CoV-2 phagocytosis. 2020 , 143, 110108	2
2115	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. 2020 , 18, 367-375	15
2114	Coagulopathy in COVID-19: Focus on vascular thrombotic events. 2020 , 146, 32-40	31
2113	Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. 2020 , 11, 3518	104
2112	COVID-19 vaccine development and a potential nanomaterial path forward. 2020 , 15, 646-655	302
2111	Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies. 2021 , 39, 4449-4461	11
2110	Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. 2020 , 21,	46
2109	Rapid development and deployment of high-volume vaccines for pandemic response. 2020 , 2, e10060	24
2108	Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae. 2020 , 107, 383-416	9
2107	Immunoglobulin fragment F(ab') against RBD potentially neutralizes SARS-CoV-2 in vitro. 2020 , 182, 104868	34
2106	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. 2020 , 5, 871-883	26
2105	Immune response in COVID-19: A review. 2020 , 13, 1619-1629	143
2104	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. 2020 , 257, 118075	57
2103	Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease. 2020 , 144, 110027	6

2102	ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. 2020 , 62, 101123	70
2101	Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation. 2020 , 100, 107695	17
2100	Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19). 2020 , 78,	21
2099	SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. 2020 , 69, 1875-1886	35
2098	COVID-19: Recent advances in epidemiology, virology, etiopathogenesis, clinical trials and vaccine development. 2020 , 7, 18-27	3
2097	Incidental diagnosis of lung adenocarcinoma following coronavirus OC 43 severe pneumonia. 2020 , 90,	4
2096	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. <i>Cell</i> , 2020 , 182, 843-854.e12	56.2 185
2095	Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. 2020 , 883, 173375	49
2094	A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. 2020 , 164, 66-76	25
2093	The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor. 2020 , 92, 10930-10934	26
2092	Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. 2020 , 31, 2021-2045	36
2091	The epidemiology and therapeutic options for the COVID-19. 2020 , 3, 71-84	7
2090	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. 2020 , 21,	22
2089	Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. 2020 , 12, 1647-1656	33
2088	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. <i>Cell</i> , 2020 , 182, 1284-1294.e8	52.4 899
2087	and expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. 2020 , 8,	26
2086	Pathogenesis and management of myocardial injury in coronavirus disease 2019. 2020 , 22, 1994-2006	19
2085	Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. 2020 , 11, 3618	89

2084	The Anatomic Pathology laboratory adjustments in the era of COVID-19 pandemic: The experience of a laboratory in a Portuguese central hospital. 2020 , 48, 151560	5
2083	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. 2020 , 27, 846-854	275
2082	Scientific solidarity in the face of the COVID-19 pandemic: researchers, publishers, and medical associations. 2020 , 2, 56-59	4
2081	ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allosteric and Evaluation of the Potential Development of ACE2 Modulators. 2020 , 15, 1682-1690	17
2080	Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications. 2020 , 2, 1-6	9
2079	Current and Future Direct-Acting Antivirals Against COVID-19. 2020 , 11, 587944	10
2078	Leveraging glycomics data in glycoprotein 3D structure validation with Privateer. 2020 , 16, 2523-2533	6
2077	Structural Characterization of N-Linked Glycans in the Receptor Binding Domain of the SARS-CoV-2 Spike Protein and their Interactions with Human Lectins. 2020 , 132, 23971-23979	6
2076	Profile of SARS-CoV-2. 2020 , 132, 635-644	2
2075	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. 2020 , 6, 6540-6555	13
2074	Virus Irradiation and COVID-19 Disease. 2020 , 8,	4
2073	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. 2020 , 21,	2
2072	Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. 2020 , 117, 29274-29282	13
2071	screening and molecular dynamics of phytochemicals from Indian cuisine against SARS-CoV-2 M. 2020 , 1-15	2
2070	Global SNP analysis of 11,183 SARS-CoV-2 strains reveals high genetic diversity. 2021 , 68, 3288-3304	29
2069	Impact of SARS-CoV-2 on Male Reproductive Health: A Review of the Literature on Male Reproductive Involvement in COVID-19. 2020 , 7, 594364	12
2068	Renal Carcinoma Is Associated With Increased Risk of Coronavirus Infections. 2020 , 7, 579422	8
2067	SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. 2020 , 9,	72

2066	SARS-CoV-2 Targets by the pscRNA Profiling of ACE2, TMPRSS2 and Furin Proteases. 2020 , 23, 101744	29
2065	SSSCPreds: Deep Neural Network-Based Software for the Prediction of Conformational Variability and Application to SARS-CoV-2. 2020 , 5, 30556-30567	3
2064	SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. 2020 , 11, 5885	230
2063	Ocular surface manifestation of COVID-19 and tear film analysis. 2020 , 10, 20178	34
2062	Computational investigation for identification of potential phytochemicals and antiviral drugs as potential inhibitors for RNA-dependent RNA polymerase of COVID-19. 2020 , 1-16	3
2061	Natural Products Database Screening for the Discovery of Naturally Occurring SARS-Cov-2 Spike Glycoprotein Blockers. 2020 , 5, 13309-13317	11
2060	The dark side of the spoon - glucose, ketones and COVID-19: a possible role for ketogenic diet?. 2020 , 18, 441	17
2059	The Secretive Liaison of Particulate Matter and SARS-CoV-2. A Hypothesis and Theory Investigation. 2020 , 11, 579964	6
2058	The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be. 2020 , 11, 594019	26
2057	Amino acid interacting network in the receptor-binding domain of SARS-CoV-2 spike protein.. 2020 , 10, 39831-39841	12
2056	Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate. 2020 , 9, 2653-2662	11
2055	Cardiovascular Manifestations of COVID-19 Infection. 2020 , 9,	49
2054	Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs. 2020 , 11,	22
2053	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. 2020 , 28, 867-879.e5	168
2052	Recombinant vaccines for COVID-19. 2020 , 16, 2905-2912	26
2051	Systems Biology Approaches for Therapeutics Development Against COVID-19. 2020 , 10, 560240	5
2050	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. 2020 , 10, 587269	199
2049	FRETing over SARS-CoV-2: Conformational Dynamics of the Spike Glycoprotein. 2020 , 28, 778-779	1

2048	Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. 2020 , 53, 1315-1330.e9	99
2047	SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. 2020 , 11, 6013	450
2046	HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. 2020 , 2, 1391-1400	95
2045	The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. 2020 , 9,	14
2044	An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. 2020 , 9,	17
2043	Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions. 2020 ,	51
2042	Molecular docking and dynamic simulations of some medicinal plants compounds against SARS-CoV-2: an in silico study. 2020 , 14, 1563-1570	10
2041	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. 2020 , 53, 1272-1280.e5	112
2040	Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. 2020 , 3, 715	8
2039	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. 2020 , 117, 32105-32113	96
2038	The role of artificial intelligence in tackling COVID-19. 2020 , 15, 717-724	37
2037	SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain. 2020 , 23, 101839	84
2036	Impact of Diabetes in Patients Diagnosed With COVID-19. 2020 , 11, 576818	35
2035	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. 2020 , 7, 605236	60
2034	Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development. 2020 , 9,	0
2033	Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. 2020 , 8, 1539	10
2032	In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis. 2020 , 10, 20584	29
2031	Investigation of the Effect of Temperature on the Structure of SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations. 2020 , 7, 583523	21

2030	Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease. 2020 , 25,	23
2029	Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study. 2020 , 173, 614-622	29
2028	Reliability of serological tests for COVID-19: comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. 2020 , 6, e04929	12
2027	Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. 2020 , 588, 327-330	339
2026	In-silico drug repurposing for targeting SARS-CoV-2 main protease (M). 2020 , 1-8	14
2025	Enhancing host cell infection by SARS-CoV-2. 2020 , 370, 765-766	33
2024	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. 2020 , 28, 880-891.e8	70
2023	Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. 2020 , 146, 111805	18
2022	Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19. 2020 , 1-16	7
2021	SARS coronavirus 2: from genome to infectome. 2020 , 21, 318	30
2020	Monitoring and Support for Elderly People Using LoRa Communication Technologies: IoT Concepts and Applications. 2020 , 12, 206	11
2019	An Analysis Review of Detection Coronavirus Disease 2019 (COVID-19) Based on Biosensor Application. 2020 , 20,	29
2018	Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. 2020 , 11, 6122	141
2017	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. 2020 , 588, 682-687	651
2016	Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. 2020 , 16, 2913-2920	16
2015	SARS-CoV2 infectivity is potentially modulated by host redox status. 2020 , 18, 3705-3711	12
2014	Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit. 2020 , 12, 55649-55658	12
2013	On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies. 2020 , 5, 3655-3677	38

2012	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. 2020 , 11, 6121	36
2011	Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2. 2020 , 10, 20864	28
2010	The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor. 2020 , 8, 6603-6610	13
2009	The structural basis of accelerated host cell entry by SARS-CoV-2 2021 , 288, 5010-5020	73
2008	Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities. 2020 , 11, 594487	13
2007	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. 2020 , 25,	8
2006	Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. 2020 , 39, 644-656	90
2005	Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. 2020 , 11, 10482-10488	16
2004	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. 2020 , 11, 588409	11
2003	The Human Leukocyte Antigen Class II Immunoepitome of the SARS-CoV-2 Spike Glycoprotein. 2020 , 33, 108454	12
2002	Circulating Cytokines and Lymphocyte Subsets in Patients Who Have Recovered from COVID-19. 2020 , 2020, 7570981	8
2001	ACE2 partially dictates the host range and tropism of SARS-CoV-2. 2020 , 18, 4040-4047	14
2000	Efforts at COVID-19 Vaccine Development: Challenges and Successes. 2020 , 8,	47
1999	Epitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic. 2020 , 11, 9920-9930	6
1998	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. 2020 , 6, 80	86
1997	Dangerous Pathogens as a Potential Problem for Public Health. 2020 , 56,	6
1996	Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins. 2020 , 6, e05421	5
1995	Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity. 2020 , 68, 13982-13989	26

1994	A Hydrophobic-Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2. 2020 , 4, 2000067	9
1993	A comprehensive overview of proteomics approach for COVID 19: new perspectives in target therapy strategies. 2020 , 11, 1-10	11
1992	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. 2020 , 329	4
1991	Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 2020 , 13, 527	8
1990	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. 2020 , 11, 589474	25
1989	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. 2020 , 10, 572329	3
1988	COVID-19 and Undiagnosed Pre-diabetes or Diabetes Mellitus Among International Migrant Workers in Singapore. 2020 , 8, 584249	9
1987	The Role of Molecular Chaperones in Virus Infection and Implications for Understanding and Treating COVID-19. 2020 , 9,	12
1986	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. 2020 , 12,	20
1985	Peptide and peptide-based inhibitors of SARS-CoV-2 entry. 2020 , 167, 47-65	63
1984	Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization. 2020 , 18, 3402-3414	36
1983	Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain. 2020 , 15, e0237295	25
1982	Acute Fulminant Myocarditis in a Pediatric Patient With COVID-19 Infection. 2020 , 146,	16
1981	Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. 2020 , 21, 269-272	29
1980	Intra- and intermolecular atomic-scale interactions in the receptor binding domain of SARS-CoV-2 spike protein: implication for ACE2 receptor binding. 2020 , 22, 18272-18283	29
1979	Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. 2021 , 39, 7231-7245	29
1978	Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. 2020 , 16, 2992-3000	6
1977	Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution. 2020 , 5,	35

1976	Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?. 2020 , 319, E689-E708	22
1975	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,	16
1974	Surface Chemistry Can Unlock Drivers of Surface Stability of SARS-CoV-2 in a Variety of Environmental Conditions. 2020 , 6, 2135-2146	42
1973	Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. 2020 , 40, 603-614	7
1972	The association between cardiac injury and outcomes in hospitalized patients with COVID-19. 2020 , 15, 1415-1424	28
1971	FN3 protein fragment containing two type III fibronectin domains from <i>B. longum</i> GT15 binds to human tumor necrosis factor alpha in vitro. 2020 , 65, 102247	8
1970	Approaches and Challenges in SARS-CoV-2 Vaccine Development. 2020 , 28, 364-370	64
1969	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. 2020 , 58, 102907	75
1968	Analysis of codon usage of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) and its adaptability in dog. 2020 , 288, 198113	9
1967	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. 2020 , 147, 12-17	19
1966	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. 2020 , 27, 942-949	89
1965	[Tracing the origins of SARS-COV-2 in coronavirus phylogenies]. 2020 , 36, 783-796	7
1964	Surface engineering of personal protective equipments (PPEs) to prevent the contagious infections of SARS-CoV-2. 2020 , 36, 901-907	18
1963	Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19. 2020 , 24, 568-580	27
1962	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. 2020 ,	15
1961	Clinical trial to test the efficacy of melatonin in COVID-19. 2020 , 69, e12683	42
1960	Mess in Science and Wicked Problems. 2020 , 28, 482-504	1
1959	Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review. 2020 , 13, 2657-2665	40

1958	Increased Hepatic ACE2 Expression in NAFL and Diabetes-A Risk for COVID-19 Patients?. 2020 , 43, e134-e136	17
1957	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. 2020 , 11, 1949	163
1956	The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. 2020 , 17,	25
1955	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,	11
1954	Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin. 2020 , 6, e04647	8
1953	Interdiction of Protein Folding for Therapeutic Drug Development in SARS CoV-2. 2020 , 124, 8201-8208	7
1952	Drugs against SARS-CoV-2: What do we know about their mode of action?. 2020 , 30, 1-10	20
1951	Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. 2020 , 29, 1-15	21
1950	Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. 2020 , 70, 441-453	13
1949	SARS-CoV-2 IgG antibody responses in New York City. 2020 , 98, 115128	22
1948	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. 2020 , 584, 353-363	289
1947	NATURAL COMPOUNDS FROM DJIBOUTIAN MEDICINAL PLANTS AS INHIBITORS OF COVID-19 BY IN SILICO INVESTIGATIONS. 2020 , 52-57	1
1946	Mutations Strengthened SARS-CoV-2 Infectivity. 2020 , 432, 5212-5226	221
1945	Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. 2020 , 11, 2008	12
1944	Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development. 2020 , 8,	7
1943	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. 2020 , 55, 2556-2564	25
1942	Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. 2020 , 100, 107697	32
1941	Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach. 2020 , 11, 1663	38

1940	SARS-CoV-2 Molecular Network Structure. 2020 , 11, 870	26
1939	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. 2020 , 13,	47
1938	COVID-19: Mechanisms of Vaccination and Immunity. 2020 , 8,	43
1937	Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development. 2020 , 2020, 7201752	13
1936	Using surgical wrapping material for the fabrication of respirator masks. 2020 , 15, e0236239	6
1935	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. 2020 , 11, 1817	104
1934	Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic. 2020 , 21,	61
1933	A Thermostable mRNA Vaccine against COVID-19. <i>Cell</i> , 2020 , 182, 1271-1283.e16	56.2 255
1932	Controlling the SARS-CoV-2 spike glycoprotein conformation. 2020 , 27, 925-933	200
1931	Quantitative determination of mechanical stability in the novel coronavirus spike protein. 2020 , 12, 16409-16413	13
1930	Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads. 2021 , 39, 6324-6337	16
1929	COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. 2020 , 16, 2891-2904	36
1928	Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. 2020 , 177, 4899-4920	35
1927	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. 2020 , 369, 1505-1509	232
1926	Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. 2020 , 369, 1501-1505	450
1925	Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes. 2020 , 94,	36
1924	Natural Polymorphisms Are Present in the Furin Cleavage Site of the SARS-CoV-2 Spike Glycoprotein. 2020 , 11, 783	26
1923	Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. 2020 , 11, 1723	33

1922	Analysis of ACE2 Gene-Encoded Proteins Across Mammalian Species. 2020 , 7, 457	5
1921	A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0. 2020 , 21,	17
1920	Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic Antigens: Implications for Immune Evasion and Serologic Diagnostic Performance. 2020 , 9,	9
1919	Relationship Between Serum Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid and Organ Damage in Coronavirus 2019 Patients: A Cohort Study. 2021 , 73, 68-75	24
1918	Decoding the global outbreak of COVID-19: the nature is behind the scene. 2020 , 31, 106-112	7
1917	Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks. <i>Cell</i> , 2020 , 182, 7-9	56.2
1916	COVID-19 and SARS-CoV-2. Modeling the present, looking at the future. 2020 , 869, 1-51	90
1915	Human neutralizing antibodies elicited by SARS-CoV-2 infection. 2020 , 584, 115-119	982
1914	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. 2020 , 10, 28243-28266	25
1913	Drug Discovery Strategies for SARS-CoV-2. 2020 , 375, 127-138	51
1912	Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. 2020 , 12, 68	228
1911	Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics. 2020 , 11, 1450	21
1910	Cardiac manifestations of COVID-19 in Shenzhen, China. 2020 , 48, 861-870	42
1909	Coronavirus Disease of 2019: a Mimicker of Dengue Infection?. 2020 , 2, 1-11	20
1908	Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics. 2020 , 265, 106438	28
1907	Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions. 2020 , 11, 131-144.e6	26
1906	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). 2020 , 58, 102887	78
1905	Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019. 2020 , 48, 300060520939746	21

1904	Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. 2020 , 11, 530	43
1903	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. 2020 , 28, 745-764	9
1902	Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. 2020 , 18, 2117-2131	17
1901	SARS-CoV-2 and cancer: Are they really partners in crime?. 2020 , 89, 102068	42
1900	Cellular immune responses to covid-19. 2020 , 370, m3018	29
1899	Plasmapheresis, Anti-ACE2 and Anti-Fc γ RII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19. 2020 , 14, 2607-2611	5
1898	Probing 3CL protease: Rationally designed chemical moieties for COVID-19. 2020 , 81, 911	5
1897	Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases. 2020 , 48, 665-669	35
1896	Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019. 2020 , 190, 2013-2017	34
1895	SARS-CoV-2 Vaccine Development: Current Status. 2020 , 95, 2172-2188	61
1894	. 2020 , 24, 190-195	4
1893	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. 2020 , 41, 815-829	66
1892	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. 2020 , 43, 1028-1046	65
1891	A thermostable, closed SARS-CoV-2 spike protein trimer. 2020 , 27, 934-941	128
1890	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. 2020 , 1,	10
1889	Medicinal Plants as Sources of Active Molecules Against COVID-19. 2020 , 11, 1189	73
1888	Orientation of immobilized antigens on common surfaces by a simple computational model: Exposition of SARS-CoV-2 Spike protein RBD epitopes. 2020 , 265, 106441	6
1887	New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?. 2020 , 356, 104187	13

1886	Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. 2020 , 7, 551-557	43
1885	The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. 2020 , 13, 1601-1610	60
1884	Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation. 2020 , 318, 113968	9
1883	Does SARS-CoV-2 Bind to Human ACE2 More Strongly Than Does SARS-CoV?. 2020 , 124, 7336-7347	54
1882	Dynamic Asymmetry Exposes 2019-nCoV Prefusion Spike. 2020 , 11, 7021-7027	22
1881	Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. 2020 , 6, 2319-2336	27
1880	Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. 2020 , 14, 10616-10623	54
1879	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. 2020 , 584, 437-442	1167
1878	Ozone: A Potential Oxidant for COVID-19 Virus (SARS-CoV-2). 2020 , 42, 378-385	44
1877	Deciphering the protein motion of S1 subunit in SARS-CoV-2 spike glycoprotein through integrated computational methods. 2021 , 39, 6705-6712	7
1876	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. 2020 , 369, 1261-1265	269
1875	Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. 2020 , 9, 88	31
1874	Biventricular strain by speckle tracking echocardiography in COVID-19: findings and possible prognostic implications. 2021 , 17, 663-667	16
1873	Prospects for RNAi Therapy of COVID-19. 2020 , 8, 916	40
1872	Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches. 2020 , 11, 1784	54
1871	Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach. 2020 , 8,	30
1870	In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy. 2020 , 26, 663-669	36
1869	G-quadruplex based biosensor: A potential tool for SARS-CoV-2 detection. 2020 , 167, 112494	47

1868	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. 2020 , 885, 173450	9
1867	Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. 2020 , 56,	98
1866	A palindromic RNA sequence as a common breakpoint contributor to copy-choice recombination in SARS-COV-2. 2020 , 165, 2341-2348	25
1865	An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. 2020 , 181, 104882	25
1864	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. 2020 , 258, 118166	43
1863	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. 2020 , 258, 118185	55
1862	Structure of Furin Protease Binding to SARS-CoV-2 Spike Glycoprotein and Implications for Potential Targets and Virulence. 2020 , 11, 6655-6663	32
1861	Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. 2020 , 41, 1141-1149	739
1860	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. 2020 , 27, 950-958	175
1859	The potential role of the carotid body in COVID-19. 2020 , 319, L620-L626	19
1858	The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. 2020 , 9,	66
1857	The D614G substitution in the S gene and clinical information for patients with COVID-19 detected in Hong Kong. 2020 , 130, 104550	8
1856	Inducible Epithelial Resistance against Coronavirus Pneumonia in Mice. 2020 , 63, 540-541	8
1855	Anticoagulant and signaling functions of antithrombin. 2020 , 18, 3142-3153	13
1854	"Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. 2020 , 8,	12
1853	High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. 2020 , 34, 3400-3410	4
1852	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> , 2020 , 182, 1295-1310.e20	56.2 935
1851	Peripheral facial paralysis as presenting symptom of COVID-19 in a pregnant woman. 2020 , 13,	27

1850	Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. 2020 , 190, 2290-2303	144
1849	Potential diagnostics and therapeutic approaches in COVID-19. 2020 , 510, 488-497	25
1848	Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. 2020 , 124, 103967	38
1847	Systemic Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. 2020 , 60, 5735-5745	14
1846	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. 2020 , 584, 450-456	848
1845	Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. 2020 , 35, 288-301	82
1844	SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. 2020 , 21,	35
1843	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. 2020 , 9,	1
1842	Immune Response and COVID-19: A mirror image of Sepsis. 2020 , 16, 2479-2489	32
1841	Molecular diagnostic technologies for COVID-19: Limitations and challenges. 2020 , 26, 149-159	137
1840	Advanced Analysis of Biosensor Data for SARS-CoV-2 RBD and ACE2 Interactions. 2020 , 92, 11520-11524	22
1839	Cardiovascular manifestation and treatment in COVID-19. 2020 , 83, 704-709	16
1838	Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors. 2020 , 13, 1-17	48
1837	A brief analysis and hypotheses about the risk of COVID-19 for people with type 1 and type 2 diabetes mellitus. 2020 , 19, 1-5	5
1836	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. 2020 , 57, 236-243	23
1835	ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population. 2020 , 510, 455-458	35
1834	Potently neutralizing and protective human antibodies against SARS-CoV-2. 2020 , 584, 443-449	609
1833	Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. 2020 , 94,	78

1832	COVID-19 and COPD. 2020 , 56,	124
1831	Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. 2020 , 12, 70	51
1830	ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle. 2020 , 11, 574753	26
1829	Transmission of SARS-CoV-2 in South Asian countries: molecular evolutionary model based phylogenetic and mutation analysis. 2020 , 4, 533	2
1828	Three-Dimensional Structures of Carbohydrates and Where to Find Them. 2020 , 21,	8
1827	Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. 2020 , 45, 1	24
1826	SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic. 2020 , 5, 252	8
1825	COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. 2020 , 5, 256	88
1824	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. 2020 , 11,	69
1823	COVID-19 and iron dysregulation: distant sequence similarity between hepcidin and the novel coronavirus spike glycoprotein. 2020 , 15, 19	35
1822	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. 2020 , 10, 575404	3
1821	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. 2020 , 11, 579250	50
1820	Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity. 2020 , 9, e1189	23
1819	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. 2020 , 10, 18149	41
1818	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. 2020 , 7, 588618	49
1817	Prevention of SARS-CoV-2 cell entry: insight from interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2. 2020 , 1-25	17
1816	Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment. 2020 , 14, 403-412	12
1815	Implications of COVID-19 Pandemic on Evolution of Diabetes in Malaria-Endemic African Region. 2020 , 2020, 8205261	0

1814	New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release. 2020 , 16, 1176934320965149	24
1813	Genetic Spectrum and Distinct Evolution Patterns of SARS-CoV-2. 2020 , 11, 593548	23
1812	Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age. 2020 , 11, 590787	17
1811	COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms. 2020 , 2, 2109-2125	12
1810	The global population of SARS-CoV-2 is composed of six major subtypes. 2020 , 10, 18289	29
1809	Clinical manifestations and pathogen characteristics in children admitted for suspected COVID-19. 2020 , 14, 776-785	6
1808	analysis of ACE2 orthologues to predict animal host range with high susceptibility to SARS-CoV-2. 2020 , 10, 483	6
1807	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980	20
1806	A graph-based approach identifies dynamic H-bond communication networks in spike protein S of SARS-CoV-2. 2020 , 212, 107617	19
1805	Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations. 2020 , 124, 10034-10047	39
1804	Targeting Crucial Host Factors of SARS-CoV-2. 2020 , 6, 2844-2865	13
1803	Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins. 2020 , 1-20	58
1802	Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach. 2020 , 1-18	7
1801	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
1800	The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. 2020 , 9,	29
1799	Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. 2020 , 38, 100786	30
1798	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
1797	(cat's claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling. 2020 , 1-17	11

1796	High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States. 2020 , 33, 108352	23
1795	Statins and SARS-CoV-2 disease: Current concepts and possible benefits. 2020 , 14, 2063-2067	21
1794	Synthetic Carbohydrate Chemistry and Translational Medicine. 2020 , 85, 15780-15800	7
1793	Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. 2020 , 11, 5413	105
1792	Inhibition of Coronavirus Entry and by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. 2020 , 11,	33
1791	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. 2020 , 11, 576622	137
1790	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020 , 183, 1367-1382.e17	56.2 217
1789	ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection. 2020 , 148, e262	36
1788	Reformulation of the self-guided molecular simulation method. 2020 , 153, 094112	1
1787	Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2. 2020 , 17, 165	13
1786	Integrated Risk of Pandemic: Covid-19 Impacts, Resilience and Recommendations. 2020 ,	
1785	Identification of a dominant CD8 CTL epitope in the SARS-associated coronavirus 2 spike protein. 2020 , 38, 7697-7701	5
1784	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. 2020 , 4, 1188-1196	40
1783	Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy. 2020 , 10, 16099	37
1782	Quantifying the adhesive strength between the SARS-CoV-2 S-proteins and human receptor and its effect in therapeutics. 2020 , 10, 17538	7
1781	A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases. 2020 , 136, 155228	4
1780	Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects. 2020 , 165, 1626-1633	10
1779	Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. 2020 , 11, 5337	23

1778	Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community. 2020 , 17, 633-638	5
1777	Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. 2020 , 53, e12939	39
1776	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. 2020 , 26, 631-641	18
1775	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. 2020 , 117, 23652-23662	133
1774	SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. 2020 , 58,	31
1773	The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. 2020 , 11, 1880	45
1772	Host genetic factors and susceptibility to SARS-CoV-2 infection. 2020 , 32, e23497	3
1771	Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. 2020 , 11, 4378	45
1770	First neonates with severe acute respiratory syndrome coronavirus 2 infection in Romania: Three case reports. 2020 , 99, e21284	10
1769	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. 2020 , 10,	10
1768	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. 2020 , 11, 4420	151
1767	Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. 2020 , 117, 24620-24626	59
1766	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. 2020 , 19, 40	62
1765	Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations. 2020 , 11, 1039	35
1764	Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2020 , 227, 31-37.e1	19
1763	The Answer Lies in the Energy: How Simple Atomistic Molecular Dynamics Simulations May Hold the Key to Epitope Prediction on the Fully Glycosylated SARS-CoV-2 Spike Protein. 2020 , 11, 8084-8093	24
1762	Immunological considerations for COVID-19 vaccine strategies. 2020 , 20, 615-632	480
1761	SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. 2020 , 13, 120	265

1760	Coronaviruses and stress: from cellular to global. 2020 , 25, 701-705		4
1759	Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. 2020 , 11, 4417		195
1758	Switching Host Metabolism as an Approach to Dampen SARS-CoV-2 Infection. 2020 , 76, 297-303		19
1757	Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. 2020 , 6, 1722-1734		340
1756	Quinazoline-Schiff base conjugates: study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins.. 2020 , 10, 34033-34045		13
1755	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. 2020 , 370, 950-957		314
1754	Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. 2020 , 11, 2159		6
1753	Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases. 2020 , 19, 4398-4406		9
1752	SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. 2020 , 34, 14103-14119		20
1751	Can Adenosine Fight COVID-19 Acute Respiratory Distress Syndrome?. 2020 , 9,		10
1750	Human recombinant soluble ACE2 in severe COVID-19. 2020 , 8, 1154-1158		199
1749	Molecular Architecture of the SARS-CoV-2 Virus. <i>Cell</i> , 2020 , 183, 730-738.e13	56.2	385
1748	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. <i>Cell</i> , 2020 , 183, 1043-1057.e15	56.2	454
1747	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020 , 183, 1013-1023.e13	56.2	145
1746	Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis. 2020 , 144, 110254		17
1745	Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. 2020 , 22, 515-524		12
1744	Genetic grouping of SARS-CoV-2 coronavirus sequences using informative subtype markers for pandemic spread visualization. 2020 , 16, e1008269		20
1743	Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation. 2020 , 52, jrm00094		6

1742	SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?. 2020 , 21,	11
1741	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. 2020 , 3, 790-800	14
1740	Profiling and characterization of SARS-CoV-2 mutants' infectivity and antigenicity. 2020 , 5, 185	19
1739	The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives. 2020 , 33, 21-27	25
1738	Neurological Implications of Non-critically Ill Patients With Coronavirus Disease 2019 in a Fangcang Shelter Hospital in Wuhan, China. 2020 , 11, 895	4
1737	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. 2020 , 21,	32
1736	Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. 2020 , 370, 725-730	182
1735	Anal swab as a potentially optimal specimen for SARS-CoV-2 detection to evaluate hospital discharge of COVID-19 patients. 2020 , 15, 1101-1107	10
1734	Extracellular Vesicles in Viral Replication and Pathogenesis and Their Potential Role in Therapeutic Intervention. 2020 , 12,	8
1733	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. 2020 , 12,	49
1732	Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome. 2020 , 10, 14179	46
1731	A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic. 2020 , 100, 216-223	33
1730	Protein Surface Printer for Exploring Protein Domains. 2020 , 60, 5255-5264	1
1729	Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. 2020 , 10, 14214	117
1728	Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2. 2020 , 1-14	22
1727	SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig. 2020 , 94,	48
1726	Advances in Viral Diagnostic Technologies for Combating COVID-19 and Future Pandemics. 2020 , 25, 513-521	8
1725	Genome evolution of SARS-CoV-2 and its virological characteristics. 2020 , 40, 17	24

1724	A Comprehensive, Flexible Collection of SARS-CoV-2 Coding Regions. 2020 , 10, 3399-3402	22
1723	Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks, Using Evolution and Reverse Genetics. 2020 , 11, 2051	1
1722	ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. 2020 , 9,	25
1721	Thrombosis in COVID-19. 2020 , 95, 1578-1589	92
1720	Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis. 2020 , 14, 12234-12247	45
1719	Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - (Ashwagandha), (Giloy) and (Tulsi) - a molecular docking study. 2020 , 1-14	83
1718	Immune responses during COVID-19 infection. 2020 , 9, 1807836	49
1717	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. 2020 , 76, 1339-1349	86
1716	The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. 2020 , 18, 322	56
1715	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. 2020 , 11, 1818	50
1714	Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects. 2020 , 9,	17
1713	COVID-19 and Sex Differences: Mechanisms and Biomarkers. 2020 , 95, 2189-2203	91
1712	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 2020 , 11, 4303	94
1711	Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. 2020 , 26, 1676-1682	20
1710	Is Nanotechnology Helping in the Fight Against COVID-19?. 2020 , 2,	19
1709	Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection. 2020 , 9,	6
1708	Thymol and Thyme Essential Oil-New Insights into Selected Therapeutic Applications. 2020 , 25,	48
1707	Antibody response to SARS-Co-V-2, diagnostic and therapeutic implications. 2020 , 4, 1731	4

1706	Engineering photonics solutions for COVID-19. 2020 , 5, 090901	11
1705	Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. 2020 , 295, 15174-15182	19
1704	Potential protease inhibitors and their combinations to block SARS-CoV-2. 2020 , 1-15	7
1703	Naltrexone a potential therapeutic candidate for COVID-19. 2020 , 1-8	8
1702	Smoking and COVID-19: Adding Fuel to the Flame. 2020 , 21,	31
1701	Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction. 2020 , 25,	6
1700	Control Measures for SARS-CoV-2: A Review on Light-Based Inactivation of Single-Stranded RNA Viruses. 2020 , 9,	29
1699	The overlooked chamber in coronavirus disease 2019. 2020 , 7, 3483	3
1698	Vitamin D deficiency in schizophrenia implications for COVID-19 infection. 2021 , 38, 278-287	4
1697	Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. 2020 , 99, e22031	1
1696	Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?. 2020 , 10,	23
1695	Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design. 2020 , 7, 309	15
1694	Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. 2020 , 8, 559841	23
1693	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. 2020 , 8, 572885	32
1692	Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus. 2020 , 12,	26
1691	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. 2020 , 72, 2313-2330	7
1690	A Concise Review of Baseline Facts of SARS-CoV-2 for Interdisciplinary Research. 2020 , 5, 10897-10923	4
1689	investigation of spice molecules as potent inhibitor of SARS-CoV-2. 2020 , 1-15	21

1688	The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector. 2020 , 54, 1-15	11
1687	Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. 2020 , 11, 570018	23
1686	In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins. 2020 , 19, 4637-4648	25
1685	Biological fluid dynamics of airborne COVID-19 infection. 2020 , 31, 1-33	39
1684	From ACE2 to COVID-19: A multiorgan endothelial disease. 2020 , 100, 425-430	6
1683	Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. 2020 , 12,	9
1682	[COVID-19 infection-Risk of thromboembolic complications]. 2020 , 25, 1-6	2
1681	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. 2020 , 9, 2076-2090	33
1680	The relationship between hyperglycemia and the infection of COVID-19 in diabetic patients: A protocol for systematic review and meta-analysis. 2020 , 99, e21806	2
1679	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. 2020 , 15, e0238089	41
1678	The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. 2020 , 25,	4
1677	Synthesis of exfoliated multilayer graphene and its putative interactions with SARS-CoV-2 virus investigated through computational studies. 2020 , 1-10	10
1676	Structural Characterization of N-Linked Glycans in the Receptor Binding Domain of the SARS-CoV-2 Spike Protein and their Interactions with Human Lectins. 2020 , 59, 23763-23771	40
1675	Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:Serologic Testing. 2020 ,	87
1674	Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein. 2020 , 5, 81	11
1673	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 98, 1369-1383	19
1672	An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. 2020 , 10, 13866	61
1671	A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment. 2020 , 7, 186	15

1670	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. 2020 , 10, 1555	4
1669	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. 2020 , 11, 1258	61
1668	Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue. 2020 , 13, 1048-1054	13
1667	In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. 2020 , 370, 203-208	287
1666	A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. 2020 , 28, 1141-1152	28
1665	Analysis of COVID-19 Cases and Public Measures in China. 2020 , 2, 1-7	0
1664	ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. 2020 , 21, 1293-1301	119
1663	Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. 2020 , 222, 1965-1973	8
1662	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2. 2020 , 76, 651-661	38
1661	Layer-By-Layer Nanocoating of Antiviral Polysaccharides on Surfaces to Prevent Coronavirus Infections. 2020 , 25,	14
1660	Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. 2020 , 10, 14031	120
1659	Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states. 2020 , 153, 075101	64
1658	Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. 2020 , 117, 22311-22322	267
1657	COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. 2020 , 16, e1008762	96
1656	Susceptibility of the Iranian population to severe acute respiratory syndrome coronavirus 2 infection based on variants of angiotensin I converting enzyme 2. 2020 , 15, 507-514	2
1655	Beyond point of care diagnostics: Low-dimensional nanomaterials for electronic virus sensing. 2020 , 38, 050804	3
1654	A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. 2020 , 11, 4198	69
1653	Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. 2020 , 9, 1965-1973	26

1652	Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. 2020 , 21,	39
1651	Deciphering SARS-CoV-2 Virologic and Immunologic Features. 2020 , 21,	12
1650	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. 2020 , 8,	61
1649	SARS-CoV-2 ORF8 and SARS-CoV ORF8ab: Genomic Divergence and Functional Convergence. 2020 , 9,	22
1648	The Sialoside-Binding Pocket of SARS-CoV-2 Spike Glycoprotein Structurally Resembles MERS-CoV. 2020 , 12,	32
1647	Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19. 2020 , 3, 5633-5638	13
1646	Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. 2020 , 14, 11821-11830	33
1645	Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments. 2020 , 11, 595888	23
1644	Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study. 2020 , 25,	9
1643	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. 2020 , 25,	15
1642	Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review. 2020 , 12, 8630	2
1641	Screening of Natural Products Targeting SARS-CoV-2-ACE2 Receptor Interface - A MixMD Based HTVS Pipeline. 2020 , 8, 589769	11
1640	Taming the Autophagy as a Strategy for Treating COVID-19. 2020 , 9,	29
1639	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. 2021 , 74, 1088-1100	22
1638	A 3.4-Å cryo-electron microscopy structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles. 2020 , 1, e11	2
1637	A single dose of recombinant VSV- Δ spike vaccine provides protection against SARS-CoV-2 challenge. 2020 , 11, 6402	102
1636	B cell targeting by molecular adjuvants for enhanced immunogenicity. 2020 , 19, 1023-1039	3
1635	A Nanomechanical Study on Deciphering the Stickiness of SARS-CoV-2 on Inanimate Surfaces. 2020 , 12, 58360-58368	14

1634	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. 2020 , 11, 610688	90
1633	Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies. 2020 , 7, 589060	4
1632	Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. 2020 , 7, 603996	6
1631	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. 2020 , 17,	24
1630	Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?. 2020 , 21,	14
1629	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. 2020 , 3, 246-256	14
1628	Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection. 2020 , 11,	23
1627	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. 2020 , 11, 569760	12
1626	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). 2020 , 11, 571481	28
1625	Surveying the Side-Chain Network Approach to Protein Structure and Dynamics: The SARS-CoV-2 Spike Protein as an Illustrative Case. 2020 , 7, 596945	4
1624	SARS CoV-2 Organotropism Associated Pathogenic Relationship of Gut-Brain Axis and Illness. 2020 , 7, 606779	12
1623	Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2. 2020 , 11, 584158	6
1622	A New Crystal Form of the SARS-CoV-2 Receptor Binding Domain: CR3022 Complex-An Ideal Target for In-Crystal Fragment Screening of the ACE2 Binding Site Surface. 2020 , 11, 615211	3
1621	Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective. 2020 , 11, 609910	7
1620	Characterization of Structural and Energetic Differences between Conformations of the SARS-CoV-2 Spike Protein. 2020 , 13,	33
1619	Bat-Borne Coronaviruses in Jordan and Saudi Arabia: A Threat to Public Health?. 2020 , 12,	0
1618	Whole Genome Identification of Potential G-Quadruplexes and Analysis of the G-Quadruplex Binding Domain for SARS-CoV-2. 2020 , 11, 587829	20
1617	Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset. 2020 , 11, 596553	23

1616	Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. 2020 , 6,	6
1615	A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters. 2020 , 11, 614256	25
1614	Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. 2020 , 11, 596631	30
1613	Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. 2020 , 12,	5
1612	Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route. 2020 , 144, 110243	11
1611	Pandemic number five - Latest insights into the COVID-19 crisis. 2020 , 43, 305-310	3
1610	Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain. 2021 , 27, 1350.e1-1350.e5	8
1609	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. 2020 , 85, 104510	6
1608	Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays. 2020 , 52, 770-777	28
1607	Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in <i>Pichia pastoris</i> and mammalian cells. 2020 , 10, 21779	37
1606	Tracing the driving forces responsible for the remarkable infectivity of 2019-nCoV: 1. Receptor binding domain in its bound and unbound states. 2020 , 22, 28277-28285	2
1605	Interpretation of SARS-CoV-2 behaviour on different substrates and denaturation of virions using ethanol: an atomic force microscopy study.. 2020 , 10, 44079-44086	5
1604	Virtual screening of phytoconstituents from miracle herb targeting nucleocapsid protein and papain-like protease of SARS-CoV-2 for COVID-19 treatment. 2020 , 1-21	23
1603	Utilizing microbiome approaches to assist source tracking, treatment and prevention of COVID-19: Review and assessment. 2020 , 18, 3615-3622	6
1602	Neutralizing antibodies for the treatment of COVID-19. 2020 , 4, 1134-1139	52
1601	Understanding the biological role of PqqB in using molecular dynamics simulation approach. 2020 , 1-13	4
1600	Effect of protein steric constraints on the symmetry of membrane protein polyhedra. 2020 , 102, 042411	1
1599	SARS-CoV-2, Early Entry Events. 2020 , 2020, 9238696	10

1598	Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota. 2020 , 10, 575559	29
1597	ACE2 and Furin Expressions in Oral Epithelial Cells Possibly Facilitate COVID-19 Infection via Respiratory and Fecal-Oral Routes. 2020 , 7, 580796	21
1596	Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. 2020 , 7, 594495	63
1595	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. 2020 , 11, 572168	8
1594	Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients. 2020 , 11, 587013	7
1593	How Does SARS-CoV-2 Affect the Central Nervous System? A Working Hypothesis. 2020 , 11, 582345	15
1592	Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus. 2020 , 8,	11
1591	Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus. 2020 , 9,	9
1590	Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. 2020 , 13,	12
1589	Recent updates on COVID-19: A holistic review. 2020 , 6, e05706	12
1588	Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways. 2020 , 2020, 8896536	5
1587	Symptoms, epidemiology and diagnosis: A mini-review on coronavirus. 2020 , 19, 763-772	1
1586	Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity. 2020 ,	
1585	Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity. 2020 ,	
1584	Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity. 2020 ,	
1583	Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity. 2020 ,	
1582	Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19. 2020 , 5, 258	32
1581	Structures and distributions of SARS-CoV-2 spike proteins on intact virions. 2020 , 588, 498-502	461

1580	Virological and Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases. 2020 , 11, 580867	3
1579	SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle. 2020 , 21,	12
1578	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
1577	Development of a PCR-RFLP method for detection of D614G mutation in SARS-CoV-2. 2020 , 86, 104625	4
1576	Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19. 2020 , 144, 110207	2
1575	Nano-based antiviral coatings to combat viral infections. 2020 , 24, 100620	25
1574	Current Prevention of COVID-19: Natural Products and Herbal Medicine. 2020 , 11, 588508	52
1573	Coevolution, Dynamics and Allosteric Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2. 2020 , 21,	14
1572	Threading the Pieces Together: Integrative Perspective on SARS-CoV-2. 2020 , 9,	3
1571	Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. 2020 , 106, 106-116	16
1570	The SARS-CoV-2 spike protein: balancing stability and infectivity. 2020 , 30, 1059-1060	36
1569	Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. 2020 , 10, 19125	28
1568	Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. 2020 , 370, 1479-1484	138
1567	An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona. 2020 , 11,	18
1566	Man-Specific, GalNAc/T/Tn-Specific and Neu5Ac-Specific Seaweed Lectins as Glycan Probes for the SARS-CoV-2 (COVID-19) Coronavirus. 2020 , 18,	10
1565	Phylogeography of 27,000 SARS-CoV-2 Genomes: Europe as the Major Source of the COVID-19 Pandemic. 2020 , 8,	9
1564	Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. <i>Cell</i> , 2020 , 183, 1901-1912.e9	56.2 344
1563	Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 11, 9781-9787	13

1562	SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. 2020 , 6, 2238-2249	82
1561	Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. 2020 , 11, 5588	73
1560	Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection: approaches. 2020 , 1-12	2
1559	Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of leaves. 2020 , 1-16	11
1558	Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2. 2020 , 1-14	6
1557	SARS-CoV-2 mutations and where to find them: an perspective of structural changes and antigenicity of the spike protein. 2020 , 1-11	0
1556	Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. 2020 , 370, 1339-1343	441
1555	An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. 2020 , 370, 1473-1479	166
1554	Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm. 2020 , 65, 703-709	13
1553	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. 2020 , 2020, 9465398	18
1552	Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. 2020 , 25,	17
1551	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. 2020 , 8,	27
1550	Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations. 2021 , 313, 611-622	9
1549	Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs. 2020 , 126, 104054	21
1548	Separation of Permethylated -Glycans, Free Oligosaccharides, and Glycosphingolipid-Glycans Using Porous Graphitized Carbon (PGC) Column. 2020 , 10,	6
1547	Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo. 2020 , 6, 76	44
1546	Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal. 2020 , 9, 2488-2496	12
1545	Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future. 2020 , 40, 38	2

1544	CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics. 2020 , 10, 576875	22
1543	Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy. 2020 , 3, 95-100	43
1542	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. 2020 , 177, 4942-4966	51
1541	The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. 2020 , 31, 454-470	111
1540	A human monoclonal antibody blocking SARS-CoV-2 infection. 2020 , 11, 2251	685
1539	WITHDRAWN: A mechanistic analysis placental intravascular thrombus formation in COVID-19 patients. 2020 , 46, 151529	18
1538	Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. 2020 , 19, 102570	22
1537	A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. 2020 , 78, 779-784.e5	965
1536	FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. 2021 , 39, 3419-3427	60
1535	Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. 2020 , 30, 981-988	269
1534	Site-specific glycan analysis of the SARS-CoV-2 spike. 2020 , 369, 330-333	768
1533	Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. 2020 , 31, 1380-1383	305
1532	The molecular biology of intracellular events during Coronavirus infection cycle. 2020 , 31, 1-5	7
1531	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. <i>Cell</i> , 2020 , 181, 1004-1015.e15	56.2 319
1530	Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?. 2020 , 11, 1229	77
1529	Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. <i>Cell</i> , 2020 , 182, 73-84.e16	56.2 806
1528	On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2. 2020 , 285, 198021	36
1527	A spike with which to beat COVID-19?. 2020 , 18, 414	2

1526	Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank. 2020 , 287, 3703-3718	25
1525	Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps. 2020 , 11, 1076-1078	25
1524	Nanovesicles displaying functional linear and branched oligomannose self-assembled from sequence-defined Janus glycodendrimers. 2020 , 117, 11931-11939	19
1523	Is there an impact of the COVID-19 pandemic on male fertility? The ACE2 connection. 2020 , 318, E878-E880	33
1522	Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. 2020 , 31, 107725	263
1521	Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design. 2020 , 128, 104441	21
1520	Are Iranian Sulfur Mustard Gas-Exposed Survivors More Vulnerable to SARS-CoV-2? Some Similarity in Their Pathogenesis. 2020 , 14, 826-832	8
1519	Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. 2020 , 9,	55
1518	A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?. 2020 , 8,	39
1517	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. 2020 , 42, 1021-1049	78
1516	Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection?. 2020 , 143, 109842	24
1515	The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. 2020 , 21,	124
1514	Potential SARS-CoV-2 Preimmune IgM Epitopes. 2020 , 11, 932	4
1513	The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor. 2020 , 12,	94
1512	Structural basis of receptor recognition by SARS-CoV-2. 2020 , 581, 221-224	2085
1511	Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. 2020 , 581, 215-220	2961
1510	Management of the airway and lung isolation for thoracic surgery during the COVID-19 pandemic: Recommendations for clinical practice endorsed by the Association for Cardiothoracic Anaesthesia and Critical Care and the Society for Cardiothoracic Surgery in Great Britain and Ireland. 2020 , 75, 1509-1516	18
1509	DC/L-SIGNS of hope in the COVID-19 pandemic. 2020 , 92, 1396-1398	33

1508	Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. 2020 , 6, 31	423
1507	SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. 2020 , 74, e13525	204
1506	Developing a vaccine for covid-19. 2020 , 369, m1790	21
1505	Cell entry mechanisms of SARS-CoV-2. 2020 , 117, 11727-11734	1620
1504	COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?. 2020 , 115, 31	123
1503	Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. 2020 , 46, 151530	70
1502	COVID-19: The first documented coronavirus pandemic in history. 2020 , 43, 328-333	254
1501	Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19. 2020 , 41, 1818-1820	43
1500	Coronavirus Pandemic-Therapy and Vaccines. 2020 , 8,	37
1499	Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. 2020 , 12,	360
1498	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. 2020 , 8, 640-648	94
1497	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. 2020 , 84, 106560	109
1496	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. 2020 , 25, 1611-1617	45
1495	A serological assay to detect SARS-CoV-2 seroconversion in humans. 2020 , 26, 1033-1036	1111
1494	Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. 2020 , 94,	98
1493	Coronavirus Disease 2019 and the Cerebrovascular-Cardiovascular Systems: What Do We Know So Far?. 2020 , 9, e016793	25
1492	Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. 2020 , 12,	48
1491	Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. 2020 , 53, 43-52	58

1490	Conserved High Free Energy Sites in Human Coronavirus Spike Glycoprotein Backbones. 2020 , 27, 1622-1630	4
1489	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. 2020 , 368, 1274-1278	682
1488	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. 2020 , 5,	531
1487	Drug repurposing against COVID-19: focus on anticancer agents. 2020 , 39, 86	44
1486	COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission. 2020 , 14, 17	68
1485	An overview of COVID-19. 2020 , 21, 343-360	144
1484	SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. 2020 , 84, 104384	78
1483	Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses. 2020 , 10,	76
1482	Conditional cell reprogramming for modeling host-virus interactions and human viral diseases. 2020 , 92, 2440-2452	4
1481	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. 2020 , 256, 117883	62
1480	An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. 2020 , 37, 101755	104
1479	Comparing the Binding Interactions in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV. 2020 , 11, 4897-4900	63
1478	Antiviral effects of probiotic metabolites on COVID-19. 2021 , 39, 4175-4184	49
1477	Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-Related Viruses. 2020 , 11,	44
1476	COVID-19: ACE2centric Infective Disease?. 2020 , 76, 294-299	39
1475	The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. 2020 , 179, 237-246	12
1474	SARS-CoV-2 antibody testing-questions to be asked. 2020 , 146, 35-43	60
1473	[SARS-CoV-2, COVID-19 and the eye: An update on published data]. 2020 , 43, 642-652	2

1472	Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. 2020 , 84, 104389	56
1471	Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity. 2020 , 1, e6	12
1470	Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. 2020 , 11, 2806	222
1469	Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer. 2020 , 92, 2637-2647	8
1468	The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. 2020 , 143, 109883	24
1467	SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in Neuropathogenesis. 2020 , 11, 1887-1899	22
1466	SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. 2020 , 21,	34
1465	The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. 2020 , 23, 101160	115
1464	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?. 2020 , 158, 104906	44
1463	Clinical Performance of Two SARS-CoV-2 Serologic Assays. 2020 , 66, 1055-1062	143
1462	Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. 2020 , 94,	90
1461	Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. 2020 , 43, 1427-1432	47
1460	Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. 2020 , 47, 4383-4392	87
1459	A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. 2020 , 360, 5-34	56
1458	COVID-19: CADD to the rescue. 2020 , 285, 198022	13
1457	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. 2020 , 5,	44
1456	Is the kidney a target of SARS-CoV-2?. 2020 , 318, F1454-F1462	105
1455	Coronavirus Disease 2019 (COVID-19) in Neonates and Children From China: A Review. 2020 , 8, 287	24

1454	COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. 2020 , 393, 1131-1135	14
1453	Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!. 2020 , 216, 108459	65
1452	Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. 2020 , 194, 105921	305
1451	Immunology of COVID-19: Current State of the Science. 2020 , 52, 910-941	962
1450	Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. 2020 , 17, 621-630	250
1449	SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial?. 2020 , 92, 2623-2630	43
1448	Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. 2020 , 190, 1680-1690	185
1447	Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight. 2020 , 10, 1175-1191	9
1446	Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. 2020 , 6, 98-105	25
1445	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. <i>Cell</i> , 2020 , 181, 1458-1463	56.2 70
1444	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , 2020 , 182, 429-446.e14	56.2 710
1443	A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. 2020 , 28, 124-133.e4	348
1442	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152
1441	[COVID-19: Pathogenesis of a multi-faceted disease]. 2020 , 41, 375-389	12
1440	COVID-19 in rheumatic disease patients on immunosuppressive agents. 2020 , 50, 680-686	36
1439	Emergence of SARS-CoV-2 through recombination and strong purifying selection. 2020 , 6,	205
1438	Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. 2020 , 73, 366-369	83
1437	SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism. 2020 , 319, E43-E47	16

1436	Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells. 2020 , 8,	72
1435	Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond. 2020 , 12, 1199-1203	1
1434	SARS-CoV-2-A Tough Opponent for the Immune System. 2020 , 51, 589-592	49
1433	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). 2020 , 158, 104929	53
1432	Better preventing and mitigating the effects of Covid-19. 2020 , 6, FSO586	7
1431	Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control. 2020 , 41, 1137-1151	53
1430	A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. 2020 , 60, 954-975	7
1429	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. 2020 , 109, 1446-1459	34
1428	Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. 2020 , 31, 179-193	79
1427	SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. 2020 , 175, 93-98	37
1426	Interaction of the prototypical β -ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex. 2020 , 87, 107292	38
1425	Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens. 2020 , 84, 104382	20
1424	Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations. 2020 , 11, 4785-4790	98
1423	Rapid, ultrasensitive and highly specific biosensor for the diagnosis of SARS-CoV-2 in clinical blood samples. 2020 , 4, 2000-2005	32
1422	Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an insight into the comparative efficacy of repurposing antiviral drugs. 2021 , 39, 4243-4255	12
1421	What We Need to Consider During and After the SARS-CoV-2 Pandemic. 2020 , 20, 477-483	6
1420	COVID-19: Structural predictions of viral success. 2020 , 74, e13568	
1419	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise. 2020 , 15, 381-395	6

1418	Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming. 2020 , 25,	12
1417	Decoding SARS-CoV-2 Transmission and Evolution and Ramifications for COVID-19 Diagnosis, Vaccine, and Medicine. 2020 , 60, 5853-5865	57
1416	Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. 2020 , 117, 15193-15199	20
1415	ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. 2020 , 222, 556-563	194
1414	Drug repurposing using computational methods to identify therapeutic options for COVID-19. 2020 , 19, 1-9	23
1413	Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system. 2020 , 529, 257-262	22
1412	Role of RNA Guanine Quadruplexes in Favoring the Dimerization of SARS Unique Domain in Coronaviruses. 2020 , 11, 5661-5667	17
1411	Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?. 2020 , 319, L45-L47	13
1410	The Role of Single-Cell Technology in the Study and Control of Infectious Diseases. 2020 , 9,	8
1409	Full Issue PDF. 2020 , 5, I-CXXXVII	
1408	Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. 2020 , 43, 375-387	11
1407	Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug. 2020 , 256, 117970	30
1406	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. 2020 , 369, 643-650	724
1405	Focus on the 2019 novel coronavirus (SARS-CoV-2). 2020 , 15, 905-918	18
1404	ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. 2020 , 18, 537-544	170
1403	Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials. 2020 , 1-12	41
1402	The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. 2020 , 54, 51-62	50
1401	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. 2020 , 14, 7760-7782	172

1400	Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an approach. 2021 , 39, 4510-4521	53
1399	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. 2020 , 369, 650-655	854
1398	Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations. 2020 , 9,	46
1397	Tackling SARS-CoV-2: proposed targets and repurposed drugs. 2020 , 12, 1579-1601	32
1396	SARS-CoV-2 Infection: Beyond the Interstitial Pneumonia. 2020 , 360, 301-303	
1395	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. 2020 , 286, 198070	75
1394	Acute Kidney Injury in the 2019 Novel Coronavirus Disease. 2020 , 323, 1-6	30
1393	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2 485
1392	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. 2020 , 583, 290-295	1028
1391	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. 2020 , 19, 100	45
1390	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. 2020 , 21,	23
1389	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. 2020 , 9,	38
1388	Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen. 2020 , 20,	126
1387	COVID-19 and the ABO blood group connection. 2020 , 59, 102838	20
1386	SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. 2020 , 18, 222	98
1385	S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19. 2020 , 51, 718-720	2
1384	An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. 2020 , 85, 106654	24
1383	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). 2020 , 27, 72	25

1382	Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility. 2020 , 45, 1	80
1381	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. 2020 , 201, 112527	52
1380	Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. 2020 , 117, 13967-13974	200
1379	IL-15 immunotherapy is a viable strategy for COVID-19. 2020 , 54, 24-31	18
1378	Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. 2020 , 369, 1010-1014	719
1377	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. 2020 , 11, 1441	320
1376	Neuromechanisms of SARS-CoV-2: A Review. 2020 , 14, 37	66
1375	The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. 2020 , 39, 198-216	263
1374	In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. 2020 , 13, 1210-1223	127
1373	Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. 2020 , 85, 104419	16
1372	Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. 2020 , 1, 100040	268
1371	Mining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein-Protein Inhibitors: Two Test Cases Illustrated by IL1 β -L1R and p38 α -TAB1 Complexes. 2020 , 63, 7559-7568	8
1370	Cryo-EM structures of HKU2 and SARS-CoV spike glycoproteins provide insights into coronavirus evolution. 2020 , 11, 3070	20
1369	SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East. 2020 , 9, 1457-1466	91
1368	The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. 2020 , 94,	177
1367	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. 2020 , 86, 106717	53
1366	An analytical study on the awareness, attitude and practice during the COVID-19 pandemic in Riyadh, Saudi Arabia. 2020 , 13, 1446-1452	85
1365	Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein. 2020 , 92, 9895-9900	147

1364	Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19. 2020 , 14, 7783-7807	179
1363	Management of clozapine treatment during the COVID-19 pandemic. 2020 , 10, 2045125320928167	22
1362	Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. 2020 , 8, e1344	35
1361	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. 2020 , 28, 445-454.e6	187
1360	Growth, detection, quantification, and inactivation of SARS-CoV-2. 2020 , 548, 39-48	99
1359	Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV. 2020 , 124, 5907-5912	23
1358	Conditionally Reprogrammed Human Normal Airway Epithelial Cells at ALI: A Physiological Model for Emerging Viruses. 2020 , 35, 280-289	4
1357	Therapeutic potential of resveratrol against emerging respiratory viral infections. 2020 , 214, 107613	56
1356	Vaccines for COVID-19: The current state of play. 2020 , 35, 43-49	94
1355	A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. 2020 , 27, 125-136.e7	338
1354	Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane. 2020 , 124, 7128-7137	131
1353	Transmission via aerosols: Plausible differences among emerging coronaviruses. 2020 , 54, 865-868	7
1352	Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation. 2020 , 222, 734-745	96
1351	Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19. 2020 , 58,	94
1350	Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective. 2020 , 97, 662-667	54
1349	Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury. 2020 , 235, 9884-9894	42
1348	Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity. 2020 , 1, 100036	39
1347	COVID-19: Drug Targets and Potential Treatments. 2020 , 63, 12359-12386	207

1346	Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?. 2020 , 2020, 4389089	96
1345	Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis?. 2020 , 40, 1818-1829	41
1344	From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances. 2020 , 8,	3
1343	Corona virus versus existence of human on the earth: A computational and biophysical approach. 2020 , 161, 271-281	20
1342	Increased susceptibility of SARS-CoV2 infection on oral cancer patients; cause and effects: An hypothesis. 2020 , 144, 109987	6
1341	COVID-19 infection: the China and Italy perspectives. 2020 , 11, 438	49
1340	Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. 2020 , 12,	116
1339	HS as a potential defense against COVID-19?. 2020 , 319, C244-C249	26
1338	Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. 2020 , 11, 707-722	45
1337	Bioactive natural compounds against human coronaviruses: a review and perspective. 2020 , 10, 1163-1174	86
1336	Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. 2020 , 23, 101212	177
1335	The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials. 2020 , 7, 248	21
1334	Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience. 2020 , 11, 659	27
1333	Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s. 2020 , 40, 1655-1670	34
1332	Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. 2020 , 1866, 165878	404
1331	Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. 2020 , 53, 98-105.e5	260
1330	Rationale for targeting complement in COVID-19. 2020 , 12, e12642	67
1329	Discovering small-molecule therapeutics against SARS-CoV-2. 2020 , 25, 1535-1544	61

1328	Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine. 2020 , 314, 113612	24
1327	Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. 2020 , 71, 870-874	163
1326	Covid-19 and the digestive system. 2020 , 35, 744-748	398
1325	Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies. 2020 , 318, L1020-L1022	43
1324	Angiotensin Converting Enzyme 2: A Double-Edged Sword. 2020 , 142, 426-428	165
1323	Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. 2020 , 100, 1065-1075	223
1322	Coronavirus SARS-CoV-2: filtering fact from fiction in the infodemic: Q&A with virologist Professor Urs Greber. 2020 , 594, 1127-1131	9
1321	A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. 2020 , 368, 630-633	954
1320	Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. 2020 , 115, 488-494	95
1319	COVID-19 pandemic, coronaviruses, and diabetes mellitus. 2020 , 318, E736-E741	380
1318	Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. 2020 , 11, 1626	74
1317	A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. <i>Cell</i> , 2020 , 182, 722-733.e127	127
1316	Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy. 2020 , 11, 1576	20
1315	Drug treatment of coronavirus disease 2019 (COVID-19) in China. 2020 , 883, 173326	15
1314	Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach. 2020 , 162, 820-837	26
1313	Does SARS-CoV-2 Trigger Stress-Induced Autoimmunity by Molecular Mimicry? A Hypothesis. 2020 , 9,	26
1312	A contemporary review on pathogenesis and immunity of COVID-19 infection. 2020 , 47, 5365-5376	27
1311	SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. 2020 , 1866, 165889	38

1310	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. 2020 , 53, 442-455.e4	151
1309	Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. 2020 , 161,	49
1308	SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury. 2020 , 14, 229	42
1307	ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19. 2020 ,	23
1306	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. 2020 , 10, 7448-7464	102
1305	On the way from SARS-CoV-sensitive mice to murine COVID-19 model. 2020 , 6, 1-7	12
1304	Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. 2020 , 9,	61
1303	Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. 2020 , 85, 104445	108
1302	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> , 2020 , 182, 812-827.e19	56.2 2322
1301	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. 2020 , 28, 475-485.e5	252
1300	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. 2020 , 146, 285-299	28
1299	COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. 2020 , 107, 219-233	148
1298	Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection. 2020 , 1, 100052	150
1297	The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection. 2020 , 24, 9472-9477	92
1296	In pursuit of COVID-19 surgical risk stratification to manage a limited workforce and supplies in minimally invasive surgery. 2020 , 15, 416-423	4
1295	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493	59
1294	Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes cell culture. 2020 , 515, 110917	26
1293	Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. 2020 , 1221, 128823	65

1292	Docking approaches for modeling multi-molecular assemblies. 2020 , 64, 59-65	9
1291	Response by Gheblawi et al to Letter Regarding Article, "Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2". 2020 , 127, e46-e47	10
1290	Human organoids: model systems for human biology and medicine. 2020 , 21, 571-584	413
1289	Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2. 2020 , 11, 1531	27
1288	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. 2020 , 9,	46
1287	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. 2020 , 9,	29
1286	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. 2020 , 883, 173348	45
1285	Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. 2020 , 116, 1733-1741	44
1284	Hepatitis C virus vaccine design: focus on the humoral immune response. 2020 , 27, 78	9
1283	Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. 2020 , 9,	34
1282	Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design. 2020 , 8,	29
1281	SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. 2020 , 27, 763-767	273
1280	The COVID-19 pandemic. 2020 , 57, 365-388	165
1279	Angiotensin II receptors: Impact for COVID-19 severity. 2020 , 33, e13989	12
1278	COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. 2020 , 22, 1109-1119	21
1277	Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2020 , 245, 1299-1307	7
1276	Progress in the Research and Development of Anti-COVID-19 Drugs. 2020 , 8, 365	9
1275	Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. 2020 , 30, e2123	48

1274	Chloroquine: A Potential Drug in the COVID-19 Scenario. 2020 , 5, 399-410	7
1273	Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. 2020 , 181, 104873	148
1272	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. 2020 , 32, 107918	107
1271	SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle. 2020 , 114, 223-232	37
1270	Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. 2020 , 77, 100741	100
1269	El ambiente, los desplazamientos y el riesgo cardiovascular en la pandemia por COVID-19. 2020 , 27, 160-165	1
1268	Transcriptomics Curation of SARS-CoV-2 Related Host Genes in Mice With COVID-19 Comorbidity: A Pilot Study. 2020 , 2, 42-47	
1267	Coronavirus Disease 2019-COVID-19. 2020 , 33,	386
1266	Identification of Common Deletions in the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 94,	89
1265	Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19. 2020 , 10, 7034-7052	20
1264	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. 2020 , 3, e2013136	243
1263	Diabetes, infection risk and COVID-19. 2020 , 39, 101044	108
1262	A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. 2020 , 11, 937	109
1261	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. 2020 , 7, 2001474	8
1260	An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. 2020 , 58, e108	88
1259	Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells. 2020 , 20, 161-169	41
1258	COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. 2020 , 38, 970-979	487
1257	SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics. 2020 , 295, 11742-11753	30

1256	Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data. 2020 , 16, 474-491	22
1255	The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. 2020 , 127, 571-587	254
1254	Extrapulmonary manifestations of COVID-19. 2020 , 26, 1017-1032	1253
1253	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. 2020 , 26, 1422-1427	283
1252	Vaccines, convalescent plasma, and monoclonal antibodies for covid-19. 2020 , 370, m2722	10
1251	COVID-19 and coronaviral hepatitis: evidence of collateral damage. 2020 , 15, 325-329	7
1250	Pathological Aspects of COVID-19 as a Conformational Disease and the Use of Pharmacological Chaperones as a Potential Therapeutic Strategy. 2020 , 11, 1095	22
1249	ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. 2020 , 9,	19
1248	Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein. 2020 , 29, 1890-1901	117
1247	BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?. 2020 , 48, 507-517	23
1246	Delving deep into the structural aspects of a furin cleavage site inserted into the spike protein of SARS-CoV-2: A structural biophysical perspective. 2020 , 264, 106420	14
1245	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. 2020 , 28, 486-496.e6	116
1244	Neurobiology of coronaviruses: Potential relevance for COVID-19. 2020 , 143, 105007	23
1243	Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach. 2021 , 39, 5690-5705	21
1242	Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations. 2021 , 39, 5706-5721	12
1241	COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. 2020 , 34, 9843-9853	78
1240	COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. 2020 , 8, 693	58
1239	SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction. 2020 , 21,	48

1238	COVID-19: Progress in diagnostics, therapy and vaccination. 2020 , 10, 7821-7835	77
1237	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7. 2020 , 25,	2
1236	Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. 2020 , 13,	39
1235	The potential role of nanomedicine on COVID-19 therapeutics. 2020 , 11, 411-414	30
1234	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919	17
1233	SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age. 2020 , 52, 1063-1065	30
1232	The renin angiotensin aldosterone system and COVID-19. 2020 , 28, 977-984	4
1231	Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. 2020 , 257, 118056	89
1230	COVID-19 and arterial hypertension: Hypothesis or evidence?. 2020 , 22, 1120-1126	37
1229	Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. 2020 , 60, 1765-1772	40
1228	Antiviral anticoagulation. 2020 , 4, 774-788	9
1227	Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. 2020 , 12,	686
1226	The trinity of COVID-19: immunity, inflammation and intervention. 2020 , 20, 363-374	2173
1225	IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. 2020 , 507, 164-166	182
1224	Potential Applications of Plant Biotechnology against SARS-CoV-2. 2020 , 25, 635-643	80
1223	Antibody therapies for the treatment of COVID-19. 2020 , 3, 101-108	7
1222	Candidate drugs against SARS-CoV-2 and COVID-19. 2020 , 157, 104859	304
1221	Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. 2020 , 382, e102	643

1220	Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. 2020 , 368, 1499-1504	634
1219	SARS-CoV-2 productively infects human gut enterocytes. 2020 , 369, 50-54	882
1218	Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder. 2020 , 25, 299-306	11
1217	Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection. 2020 , 55,	36
1216	Master Regulator Analysis of the SARS-CoV-2/Human Interactome. 2020 , 9,	106
1215	Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence. 2020 , 5, 354-359	67
1214	COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. 2020 , 5, 518-536	162
1213	Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. 2020 , 52, 217-221	56
1212	Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles. 2020 , 92, 1609-1614	8
1211	Coronavirus membrane fusion mechanism offers a potential target for antiviral development. 2020 , 178, 104792	418
1210	Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. <i>Cell</i> , 2020 , 181, 894-904.e9	56.2 1513
1209	The Greek study in the effects of colchicine in Covid-19 complications prevention (GRECCO-19 study): Rationale and study design. 2020 , 61, 42-45	90
1208	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. 2020 , 2, 100113	280
1207	COVID-19: A promising cure for the global panic. 2020 , 725, 138277	315
1206	The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?. 2020 , 2, 296-303	33
1205	Updated Approaches against SARS-CoV-2. 2020 , 64,	160
1204	2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission. 2020 , 5,	199
1203	Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. 2020 , 11, 879	163

1202	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. 2020 , 9,	87	
1201	What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?. 2020 , 8,	53	
1200	SARS-CoV-2 epidemiology and control, different scenarios for Turkey. 2020 , 50, 509-514	11	
1199	Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. <i>Cell</i> , 2020 , 181, 905-913.e7	56.2	1293
1198	[Risks of viral contamination in healthcare professionals during laparoscopy in the Covid-19 pandemic]. 2020 , 157, S60-S63	2	
1197	Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. 2020 , 201, 1557-1559	163	
1196	Dental Care and Oral Health under the Clouds of COVID-19. 2020 , 5, 202-210	49	
1195	COVID-19 Drug Discovery Using Intensive Approaches. 2020 , 21,	40	
1194	The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. 2020 , 9,	289	
1193	A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance. 2020 , 177, 4825-4844	103	
1192	Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). 2020 , 9,	40	
1191	Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19. 2020 , 26, 2823-2825	5	
1190	RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. 2020 , 13, 950-961	244	
1189	Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2. 2020 , 81, 765-767	12	
1188	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. <i>Cell</i> , 2020 , 181, 1016-1035.e19	56.2	1326
1187	COVID-19 pathophysiology: A review. 2020 , 215, 108427	761	
1186	Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. 2020 , 43, 648-654	222	
1185	Emergence of institutional antithrombotic protocols for coronavirus 2019. 2020 , 4, 510-517	37	

1184	Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. 2020 , 56, 105998	138
1183	SARS-CoV-2: Camazotz's Curse. 2020 , 76, 136-141	35
1182	Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?. 2020 , 168, 105996	91
1181	Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. 2020 , 9, 837-842	181
1180	Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence. 2020 , 108, 236-241	82
1179	Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. 2020 , 432, 3309-3325	288
1178	Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. 2020 , 107, 154245	46
1177	Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections. 2020 , 81, 643-646	10
1176	Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. 2020 , 92, 770-775	103
1175	Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. 2020 , 92, 1386-1390	88
1174	Renin-angiotensin-aldosterone system and COVID-19 infection. 2020 , 81, 63-67	45
1173	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. 2020 , 47, 107228	77
1172	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. 2020 , 14, 407-412	515
1171	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. 2020 , 76, 14-20	652
1170	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. 2020 , 75, 2950-2973	1682
1169	Risks of viral contamination in healthcare professionals during laparoscopy in the Covid-19 pandemic. 2020 , 157, S59-S62	30
1168	A short review on antibody therapy for COVID-19. 2020 , 35, 100682	40
1167	A "One-Health" approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy. 2020 , 10, 100135	30

1166	Overview of Covid-19; its prevention and management in the light of Unani medicine. 2020 , 728, 138859	36
1165	Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. 2020 , 220, 1-13	1318
1164	Coronavirus jolts labs to warp speed. 2020 , 17, 465-468	5
1163	Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. 2021 , 39, 3409-3418	275
1162	SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability. 2020 , 13, 2168	30
1161	Biological plausibility for interactions between dietary fat, resveratrol, , and SARS-CoV illness severity. 2020 , 318, E830-E833	42
1160	The Science Underlying COVID-19: Implications for the Cardiovascular System. 2020 , 142, 68-78	482
1159	Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. 2020 , 7, 19	90
1158	SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. 2020 , 39, e105114	538
1157	Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. 2020 , 318, H1080-H1083	28
1156	Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. 2020 , 126, 1456-1474	1012
1155	A computational prediction of SARS-CoV-2 structural protein inhibitors from (Neem). 2021 , 39, 4111-4121	55
1154	SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. 2021 , 9, 19-22	35
1153	Structural Basis of SARS-CoV-2- and SARS-CoV-Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. 2021 , 61, 465-493	19
1152	Worse progression of COVID-19 in men: Is testosterone a key factor?. 2021 , 9, 53-64	58
1151	SARS-CoV-2 known and unknowns, implications for the water sector and wastewater-based epidemiology to support national responses worldwide: early review of global experiences with the COVID-19 pandemic. 2021 , 56, 57-67	14
1150	Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. 2021 , 93, 275-299	33
1149	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. 2021 , 78, 1501-1522	56

1148	Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?. 2021 , 51, 226-231	14
1147	Diabetes increases the mortality of patients with COVID-19: a meta-analysis. 2021 , 58, 139-144	47
1146	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. 2021 , 16, 4-23	30
1145	An Overview on SARS-CoV-2 (COVID-19) and Other Human Coronaviruses and Their Detection Capability via Amplification Assay, Chemical Sensing, Biosensing, Immunosensing, and Clinical Assays. 2021 , 13, 18	79
1144	In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain. 2021 , 890, 173701	6
1143	Human coronavirus spike protein-host receptor recognition. 2021 , 161, 39-53	15
1142	Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. 2021 , 31, 410-424	62
1141	Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. 2021 , 890, 173720	8
1140	Insights from nanotechnology in COVID-19 treatment. 2021 , 36, 101019	82
1139	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. 2021 , 296, 100025	24
1138	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59	1
1137	Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research. 2021 , 22, 642-663	56
1136	Severe COVID-19: A multifaceted viral vasculopathy syndrome. 2021 , 50, 151645	36
1135	LPD-12: a promising lipopeptide to control COVID-19. 2021 , 57, 106218	2
1134	Olfactory taste disorder as a presenting symptom of COVID-19: a large single-center Singapore study. 2021 , 278, 1853-1862	9
1133	Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19. 2021 , 538, 92-96	10
1132	Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics. 2021 , 17, 9-32	5
1131	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?. 2021 , 17, 275-284	3

1130	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. 2021 , 19, 5-16	15
1129	Application of Bayesian phylogenetic inference modelling for evolutionary genetic analysis and dynamic changes in 2019-nCoV. 2021 , 22, 896-904	1
1128	Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. 2021 , 89, 104490	43
1127	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53	13
1126	Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?. 2021 , 82, 38-48	18
1125	Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. 2021 , 82, 86-96	28
1124	Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. 2021 , 2, 99-112.e7	154
1123	Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. 2021 , 17, 62-83	8
1122	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. 2021 , 60, 9789-9802	23
1121	Antivirals for COVID-19: A critical review. 2021 , 9, 90-98	79
1120	Bats and humans during the SARS-CoV-2 outbreak: The case of bat-coronaviruses from Mexico. 2021 , 68, 987-992	6
1119	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. 2021 , 133, 9873-9886	4
1118	COVID-19 and Hartnup disease: an affair of intestinal amino acid malabsorption. 2021 , 26, 1647-1651	4
1117	Coagulation dysfunction is associated with severity of COVID-19: A meta-analysis. 2021 , 93, 962-972	16
1116	Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. 2021 , 76, 483-496	68
1115	Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2. 2021 , 68, 318-332	4
1114	Neurology and the COVID-19 Pandemic: Gathering Data for an Informed Response. 2021 , 11, e48-e63	4
1113	What HIV in the Brain Can Teach Us About SARS-CoV-2 Neurological Complications?. 2021 , 37, 255-265	7

1112	Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors. 2021 , 13, e1657	12
1111	COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. 2021 , 51, 313-329	44
1110	Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. 2021 , 31, e2176	67
1109	Children were less frequently infected with SARS-CoV-2 than adults during 2020 COVID-19 pandemic in Warsaw, Poland. 2021 , 40, 541-547	7
1108	Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19. 2021 , 99, 115197	9
1107	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862	10
1106	Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic. 2021 , 85, 153311	25
1105	Characteristics of SARS-CoV-2 and COVID-19. 2021 , 19, 141-154	1287
1104	Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients. 2021 , 22, 1254-1266	33
1103	Protective association of angiotensin blockade with influenza: a result of immortal time bias?. 2021 , 7, e58-e59	2
1102	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. 2021 , 22, 1239-1253	52
1101	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. 2021 , 44, 13-34	59
1100	SARS-CoV-2 Induces a More Robust Innate Immune Response and Replicates Less Efficiently Than SARS-CoV in the Human Intestines: An Ex Vivo Study With Implications on Pathogenesis of COVID-19. 2021 , 11, 771-781	26
1099	Evolution of SARS-CoV-2 genome from December 2019 to late March 2020: Emerged haplotypes and informative Tag nucleotide variations. 2021 , 93, 2010-2020	4
1098	Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response During SARS-CoV-2 Infection. 2021 , 58, 520-535	39
1097	Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement. 2021 , 289, 523-531	35
1096	Overexpression of the SARS-CoV-2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia. 2021 , 253, 17-30	23
1095	Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19. 2021 , 85, 153310	36

1094	Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. 2020 , 12, 987-990	13
1093	SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?. 2021 , 1486, 15-38	35
1092	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. 2021 , 890, 173620	16
1091	The novel SARS-CoV-2 pandemic: Possible environmental transmission, detection, persistence and fate during wastewater and water treatment. 2021 , 765, 142746	39
1090	COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. 2021 , 97, 312-320	172
1089	The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. 2021 , 72, e901-e913	19
1088	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. 2021 , 538, 192-203	93
1087	Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. <i>Cell</i> , 2021 , 184, 76-91.e13	56.2 202
1086	Perspectives on mechanistic implications of ROS inducers for targeting viral infections. 2021 , 890, 173621	5
1085	Renin-angiotensin system at the interface of COVID-19 infection. 2021 , 890, 173656	12
1084	Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. 2021 , 147, 510-519.e5	61
1083	A chronicle of SARS-CoV-2: Seasonality, environmental fate, transport, inactivation, and antiviral drug resistance. 2021 , 405, 124043	46
1082	Regional differences in ACE2 expression in the sinonasal mucosa of adult Chinese patients with chronic rhinosinusitis. 2021 , 76, 1565-1568	5
1081	SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: a review. 2021 , 40, 188-192	11
1080	Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. 2020 , 100058	62
1079	Potential neurological manifestations of COVID-19: a narrative review. 2021 , 1-11	10
1078	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. 2021 , 87, 2078-2088	21
1077	Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection. 2021 , 64, 79-88	28

1076	Is a healthy microbiome responsible for lower mortality in COVID-19?. 2020 , 76, 1-11	15
1075	Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. 2021 , 31, e2183	19
1074	Computational Intelligence in Vaccine Design Against COVID-19. 2021 , 311-329	7
1073	Exploring the intrinsic dynamics of SARS-CoV-2, SARS-CoV and MERS-CoV spike glycoprotein through normal mode analysis using anisotropic network model. 2021 , 102, 107778	6
1072	The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. 2021 , 135, 170428	5
1071	Review of COVID-19 Antibody Therapies. 2021 , 50, 1-30	15
1070	COVID-19 Related Cerebrovascular Thromboembolic Complications in Three Young Patients. 2020 , 12, 321-328	6
1069	Why Does the Novel Coronavirus Spike Protein Interact so Strongly with the Human ACE2? A Thermodynamic Answer. 2021 , 22, 865-875	21
1068	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. 2021 , 23, 101-110	11
1067	Repositioning microbial biotechnology against COVID-19: the case of microbial production of flavonoids. 2021 , 14, 94-110	11
1066	A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2). 2021 , 171, 112715	79
1065	Learning from the past: development of safe and effective COVID-19 vaccines. 2021 , 19, 211-219	75
1064	SARS-CoV 2; Possible alternative virus receptors and pathophysiological determinants. 2021 , 146, 110368	8
1063	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021 , 223, 197-205	119
1062	Comparison of SARS-CoV-2 serological tests with different antigen targets. 2021 , 134, 104690	37
1061	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. 2021 , 39, 197-201	34
1060	N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. 2021 , 41, 335-344	9
1059	Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections. 2021 , 320, L158-L163	9

1058	Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL and PL), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). 2021 , 891, 173759	35
1057	One year update on the COVID-19 pandemic: Where are we now?. 2021 , 214, 105778	70
1056	Assessing the consequences of environmental exposures on the expression of the human receptor and proteases involved in SARS-CoV-2 cell-entry. 2021 , 195, 110317	7
1055	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. 2021 , 29, 23-31.e4	198
1054	Exploring the potential of foodborne transmission of respiratory viruses. 2021 , 95, 103709	7
1053	Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. 2021 , 288, 114025	50
1052	Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. 2021 , 31, 25-36	53
1051	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. 2021 , 17, 1635-1649	9
1050	SARS-CoV-2: Targeted managements and vaccine development. 2021 , 58, 16-29	21
1049	The flexibility of ACE2 in the context of SARS-CoV-2 infection. 2021 , 120, 1072-1084	52
1048	Occurrence, fate and removal of SARS-CoV-2 in wastewater: Current knowledge and future perspectives. 2021 , 9, 104870	30
1047	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426	11
1046	The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model. 2021 , 160, 1647-1661	39
1045	Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. 2021 , 97, 836-853	15
1044	Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein. 2021 , 180, 143-148	28
1043	Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope. 2021 , 90, 107156	3
1042	Neurological manifestations of coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19. 2021 , 1-8	8
1041	Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. 2021 , 128, 204-212	53

1040	Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. 2021 , 174, 69-79	271
1039	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. 2021 , 538, 187-191	39
1038	Severe acute respiratory syndrome coronavirus 2 infection reaches the human nervous system: How?. 2021 , 99, 750-777	20
1037	Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19. 2021 , 768, 145313	12
1036	SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. 2021 , 137, 106823	33
1035	Potential of algal metabolites for the development of broad-spectrum antiviral therapeutics: Possible implications in COVID-19 therapy. 2020 , 35, 2296	6
1034	SARS-CoV-2: a new dimension to our understanding of coronaviruses. 2021 , 24, 19-24	10
1033	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. 2021 , 40, 108-125	24
1032	COVID-19 endocrinopathy with hindsight from SARS. 2021 , 320, E139-E150	25
1031	Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. 2021 , 292, 198235	48
1030	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. 2021 , 11, 731-753	28
1029	Structural insights into SARS-CoV-2 proteins. 2021 , 433, 166725	78
1028	The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. 2021 , 538, 104-107	52
1027	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. 2021 , 538, 108-115	36
1026	Characteristics, onset, and evolution of neurological symptoms in patients with COVID-19. 2021 , 42, 39-46	15
1025	A high-throughput multiplexed microfluidic device for COVID-19 serology assays. 2021 , 21, 93-104	20
1024	COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury. 2021 , 65, 364-372	16
1023	COVID-19: A review of therapeutic strategies and vaccine candidates. 2021 , 222, 108634	109

1022	Electrospun ultrafine fibers for advanced face masks. 2021 , 143, 100594	56
1021	Why are ACE2 binding coronavirus strains SARS-CoV/SARS-CoV-2 wild and NL63 mild?. 2021 , 89, 389-398	10
1020	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. 2021 , 29, 44-57.e9	525
1019	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. 2021 , 17, 11-30	293
1018	In well-differentiated primary human bronchial epithelial cells, TGF-1 and TGF-2 induce expression of furin. 2021 , 320, L246-L253	5
1017	Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. 2021 , 169, 100-117	25
1016	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. 2021 , 169, 168-189	35
1015	Techniques assisting peptide vaccine and peptidomimetic design. Sidechain exposure in the SARS-CoV-2 spike glycoprotein. 2021 , 128, 104124	7
1014	The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. 2021 , 433, 166748	5
1013	Enhanced SARS-CoV-2 neutralization by dimeric IgA. 2021 , 13,	178
1012	The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. 2021 , 538, 80-87	10
1011	Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. 2021 , 108, 187-196	40
1010	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. 2021 , 20, 139-153	6
1009	A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant. 2021 , 57, 504-507	15
1008	Structural basis of severe acute respiratory syndrome coronavirus 2 infection. 2021 , 16, 74-81	3
1007	Spheroids and organoids as humanized 3D scaffold-free engineered tissues for SARS-CoV-2 viral infection and drug screening. 2021 , 45, 548-558	4
1006	Alimentary system is directly attacked by SARS-COV-2 and further prevents immune dysregulation caused by COVID-19. 2021 , 75, e13893	1
1005	Dynamic anti-spike protein antibody profiles in COVID-19 patients. 2021 , 103, 540-548	11

1004	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102	7
1003	Prediction of putative epitope-based vaccine against all corona virus strains for the Chinese population: Approach toward development of vaccine. 2021 , 65, 154-160	0
1002	T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research. 2021 , 25, 1274-1289	13
1001	Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. 2021 , 7,	132
1000	Therapeutic Implications of COVID-19 for the Interventional Cardiologist. 2021 , 26, 203-216	3
999	Genomic analysis of SARS-CoV-2 reveals local viral evolution in Ghana. 2021 , 246, 960-970	9
998	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. 2021 , 26, 311-329	0
997	microRNA-146a and -155, upregulated by periodontitis and type 2 diabetes in oral fluids, are predicted to regulate SARS-CoV-2 oral receptor genes. 2021 , 92, 35-43	10
996	Viral targets for vaccines against COVID-19. 2021 , 21, 73-82	402
995	Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19. 2021 , 22, 1371-1378	0
994	Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2. 2021 , 129, 104156	20
993	DNA vaccines against COVID-19: Perspectives and challenges. 2021 , 267, 118919	78
992	Big-Data Glycomics: Tools to Connect Glycan Biosynthesis to Extracellular Communication. 2021 , 46, 284-300	11
991	Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects. 2020 ,	39
990	SARS-CoV-2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms. 2021 , 171, 3-6	8
989	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. 2021 , 538, 137-144	8
988	Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics. 2021 , 538, 40-46	4
987	3D culture models to study SARS-CoV-2 infectivity and antiviral candidates: From spheroids to bioprinting. 2021 , 44, 31-42	11

986	The inhibitory effect of a coronavirus spike protein fragment with ACE2. 2021 , 120, 1001-1010	8
985	Technical considerations to development of serological tests for SARS-CoV-2. 2021 , 224, 121883	12
984	Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease. 2020 , 8, 595097	10
983	Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. 2020 , 11, 592908	27
982	Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy. 2021 , 1, 2000024	4
981	Hypothetical dysfunction of the epithelial sodium channel may justify neurohumoral blockade in coronavirus disease 2019. 2021 , 8, 171-174	6
980	Expression of ACE2, TMPRSS2, and Furin in Mouse Ear Tissue, and the Implications for SARS-CoV-2 Infection. 2021 , 131, E2013-E2017	15
979	Non-viral COVID-19 vaccine delivery systems. 2021 , 169, 137-151	83
978	A multiscale coarse-grained model of the SARS-CoV-2 virion. 2021 , 120, 1097-1104	54
977	Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. 2021 , 26, 1044-1059	44
976	Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. 2021 , 296, 100135	28
975	The Perspective of Coronavirus Disease Outbreak: Epidemiology, Transmission, and Possible Treatment. 2021 , 21, 78-85	3
974	Determinants of circulating angiotensin-converting enzyme 2 protein levels in the general population. 2021 , 84, 104-105	6
973	SARS-CoV-2 vaccine candidates in rapid development. 2021 , 17, 644-653	18
972	Coronavirus biology and replication: implications for SARS-CoV-2. 2021 , 19, 155-170	830
971	Molecular diversity of coronavirus host cell entry receptors. 2021 , 45,	37
970	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021 , 223, 56-61	42
969	Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M and spike protein: Drug repurposing approach. 2021 , 82, 217-229	6

968	Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19. 2021 , 538, 132-136	21
967	COVID-19 diagnosis -A review of current methods. 2021 , 172, 112752	166
966	Nano-targeting lessons from the SARS-CoV-2. 2021 , 36, 101012	4
965	An innovative method for the selection of inhibitors of the viral spike-glycoprotein of the SARS-CoV. 2021 , 19, 2050043	
964	Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. 2021 , 25, 421-433	14
963	Mathematical perspective of Covid-19 pandemic: Disease extinction criteria in deterministic and stochastic models. 2021 , 142, 110381	16
962	Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?. 2021 , 85, 153396	15
961	Exploring lectin-glycan interactions to combat COVID-19: Lessons acquired from other enveloped viruses. 2021 , 31, 358-371	15
960	Is there a role for childhood vaccination against COVID-19?. 2021 , 32, 9-16	13
959	Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. 2020 , 4, 2000172	14
958	Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. 2021 , 17, 113-121	42
957	Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity?. 2021 , 39, 35-47	16
956	Ozone therapy in COVID-19: A narrative review. 2021 , 291, 198207	18
955	Comprehensive Landscape of Heparin Therapy for COVID-19. 2021 , 254, 117232	14
954	Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein. 2021 , 35, 195-207	23
953	Union is strength: antiviral and anti-inflammatory drugs for COVID-19. 2021 , 26, 229-239	15
952	COVID-19 and Major Organ Thromboembolism: Manifestations in Neurovascular and Cardiovascular Systems. 2021 , 30, 105427	10
951	Modeling in the Time of COVID-19: Statistical and Rule-based Mesoscale Models. 2021 , 27, 722-732	7

950	Structural basis of SARS-CoV-2 spike protein induced by ACE2. 2021 , 37, 929-936	11
949	Comprehensive annotations of the mutational spectra of SARS-CoV-2 spike protein: a fast and accurate pipeline. 2021 , 68, 1625-1638	16
948	Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. 2021 , 72, 122-130	13
947	Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk. 2021 , 41, 850-859	43
946	Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain. 2021 , 31, 181-187	23
945	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. 2021 , 41, 72-135	15
944	Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition. 2021 , 35, 908-919	7
943	Elevated plasma sTIM-3 levels in patients with severe COVID-19. 2021 , 147, 92-98	14
942	CoV3D: a database of high resolution coronavirus protein structures. 2021 , 49, D282-D287	29
941	Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. 2021 , 236, 2364-2392	43
940	Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review. 2021 , 15, 183-195	8
939	Single-cell transcriptomic atlas of primate cardiopulmonary aging. 2021 , 31, 415-432	31
938	COVID-19 and diabetes; Possible role of polymorphism and rise of telemedicine. 2021 , 15, 4-9	7
937	Origin-independent analysis links SARS-CoV-2 local genomes with COVID-19 incidence and mortality. 2021 , 22, 905-913	0
936	COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. 2021 , 17, 113-131	8
935	Potential Pathogenicity Determinants Identified from Structural Proteomics of SARS-CoV and SARS-CoV-2. 2021 , 38, 702-715	12
934	Alpha-1-antitrypsin: A possible host protective factor against Covid-19. 2021 , 31, e2157	27
933	History and Recent Advances in Coronavirus Discovery. 2021 , 3	2

932 COVID-19: A Novel Disease. **2021**, 7-19

931 Chemical design principles of next-generation antiviral surface coatings. **2021**, 50, 9741-9765

5

930 SARS-CoV-2 becoming more infectious as revealed by algebraic topology and deep learning. **2021**, 21, 31-36

929 The lethal triad: SARS-CoV-2 Spike, ACE2 and TMPRSS2. Mutations in host and pathogen may affect the course of pandemic.

0

928 Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2. **2021**,

927 COVID-19 Dynamics: A Heterogeneous Model. **2020**, 8, 558368

2

926 SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host. **2021**, 79,

2

925 Are electronic cigarettes and vaping effective tools for smoking cessation? Limited evidence on surgical outcomes: a narrative review. **2021**, 13, 384-395

2

924 COVID-19 and Renin Angiotensin Aldosterone System: A Pharmacogenomic View. **2021**, 28, e136-e139

923 The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?. **2021**, 17, 1476-1485

11

922 BanLec-eGFP Chimera as a Tool for Evaluation of Lectin Binding to High-Mannose Glycans on Microorganisms. **2021**, 11,

4

921 Application of Nanotechnology in the COVID-19 Pandemic. **2021**, 16, 623-649

40

920 How glycobiology can help us treat and beat the COVID-19 pandemic. **2021**, 296, 100375

12

919 Correlative Multi-scale Cryo-imaging Unveils SARS-CoV-2 Assembly and Egress. **2021**,

1

918 A Generic Encapsulation to Unravel Social Spreading of a Pandemic: An Underlying Architecture. **2021**, 10, 12

1

917 Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation. **2021**, 17, 1925-1939

5

916 Connections between biomechanics and higher infectivity: a tale of the D614G mutation in the SARS-CoV-2 spike protein. **2021**, 6, 11

4

915 A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations. **2021**, 16, 815-830

21

914	Population Dynamics and Structural Effects at Short and Long Range Support the Hypothesis of the Selective Advantage of the G614 SARS-CoV-2 Spike Variant. 2021 , 38, 1966-1979	6
913	SARS-CoV-2 Host cell interactions and pathways: understanding its physiology, pathology, and targeted drug therapy. 2021 , 185-210	
912	Automated Methods for Detection and Classification Pneumonia Based on X-Ray Images Using Deep Learning. 2021 , 257-284	27
911	Tissue Distribution of ACE2 Protein in Syrian Golden Hamster () and Its Possible Implications in SARS-CoV-2 Related Studies. 2020 , 11, 579330	13
910	Respiratory Tract Infections: Viruses. 2021 ,	
909	One Year of SARS-CoV-2: How Much Has the Virus Changed?. 2021 , 10,	48
908	Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. 2021 , 53, 273-282	9
907	Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders. 2021 , 9, 20503121211002996	4
906	COVID-19-Related Giant Coronary Aneurysms in an Infant with Multisystem Inflammatory Disorder in Children: The First Case Report from the United Arab Emirates and the Arab Region. 2021 , 2021, 8872412	2
905	COVID-19 in Children with Asthma. 2021 , 199, 7-12	16
904	Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate.	2
903	Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. 2021 , 534, 374-380	29
902	Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by affinity maturation and SPR assay.. 2021 , 11, 14737-14745	5
901	Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVirus Disease 2019. 2021 , 12, 629119	9
900	Therapeutic targets and potential agents for the treatment of COVID-19. 2021 , 41, 1775-1797	11
899	The role and uses of antibodies in COVID-19 infections: a living review. 2021 , 2, iqab003	5
898	Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. 2021 , 18, 1	35
897	A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization. 2021 , 59,	10

896	Topography, Spike Dynamics, and Nanomechanics of Individual Native SARS-CoV-2 Virions. 2021 , 21, 2675-2680	15
895	Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa. 2021 , 7, e06035	15
894	Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. 2021 , 9,	23
893	Stabilizing the closed SARS-CoV-2 spike trimer. 2021 , 12, 244	60
892	Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. 2021 , 17, e1009292	32
891	Lattice Paths for Persistent Diagrams.. 2021 , 12929, 77-86	2
890	Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. 2021 , 10, 774-781	16
889	The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. 2021 , 296, 100536	55
888	SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets. 2021 , 22, 769-780	16
887	Detection of coronavirus in environmental surveillance and risk monitoring for pandemic control. 2021 , 50, 3656-3676	16
886	SARS-CoV-2 and the reproductive system: known and the unknown...!. 2021 , 26, 1	14
885	Learning the language of viral evolution and escape. 2021 , 371, 284-288	46
884	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. 2021 , 12, 372	176
883	Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. 2021 , 10, 1790-1806	18
882	SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. 2021 , 61, 180-202	35
881	Next-generation sequencing and RT-PCR to identify a 32-day SARS-CoV-2 carrier. 2021 , 59, e251-e254	0
880	Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. 2021 , 19, 1998-2017	9
879	Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IBV-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry.	2

878	Genomic surveillance of Nevada patients revealed prevalence of unique SARS-CoV-2 variants bearing mutations in the RdRp gene. 2021 , 48, 40-51	6
877	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. 2021 , 3, 192-197	0
876	Electrostatic interactions between the SARS-CoV-2 virus and a charged electret fibre. 2021 , 17, 4296-4303	12
875	Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions.	1
874	Public health management during COVID-19 and applications of point-of-care based biomolecular detection approaches. 2021 , 345-378	1
873	FSC-Q: a CryoEM map-to-atomic model quality validation based on the local Fourier shell correlation. 2021 , 12, 42	8
872	SARS-CoV-2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. 2021 , 58, 2465-2480	21
871	Innovative Strategies to Understand and Control COVID-19 Disease. 2021 , 209-230	
870	Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study. 2021 , 13, 9364-9370	9
869	Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. 2021 , 61, 1148-1159	6
868	Metabolic Syndrome Interacts With COVID-19. 2021 , 1, 168-177	1
867	Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19. 2021 , 43, 19-29	9
866	Dietary Supplements for COVID-19. 2021 , 1318, 499-515	2
865	Impact of COVID-19 on Dentistry. 2021 , 1318, 623-636	6
864	COVID-19: Characteristics and Therapeutics. 2021 , 10,	63
863	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. 2021 , 16, 558-570	2
862	Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors. 2021 , 7,	13
861	SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. 2021 , 12,	46

860	Understanding the Structure and Function of Viral Glycosylation by Molecular Simulations: State-of-the-Art and Recent Case Studies. 2021 , 405-415	0
859	A review on potential of natural products in the management of COVID-19.. 2021 , 11, 16711-16735	19
858	An overview of the use of biomaterials, nanotechnology, and stem cells for detection and treatment of COVID-19: towards a framework to address future global pandemics. 2021 , 4, 1-16	14
857	Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. 2021 , 12, 1209-1226	5
856	Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles. 2021 , 40, 100356	5
855	H2V: a database of human genes and proteins that respond to SARS-CoV-2, SARS-CoV, and MERS-CoV infection. 2021 , 22, 18	6
854	Elucidating Interactions Between SARS-CoV-2 Trimeric Spike Protein and ACE2 Using Homology Modeling and Molecular Dynamics Simulations. 2020 , 8, 622632	19
853	A nano perspective behind the COVID-19 pandemic. 2021 , 6, 842-855	1
852	Respiratory Disease with SARS-COV2 Infection. 2021 , 145-158	
851	Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike. 2021 , 11,	
850	Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. 2021 , 13,	73
849	SP-A and SP-D: Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties. 2020 , 11, 622598	24
848	exploration of novel protease inhibitors against coronavirus 2019 (COVID-19). 2021 , 23, 100516	5
847	Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant.	105
846	Shorter telomere lengths in patients with severe COVID-19 disease. 2021 , 13, 1-15	33
845	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. 2021 , 19, 3799-3809	12
844	Binding affinity and mechanisms of SARS-CoV-2 variants. 2021 , 19, 4184-4191	5
843	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. 2021 , 7, 183-199	60

842	The role of chemical biology in the fight against SARS-CoV-2. 2021 , 478, 157-177	2
841	Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19. 2021 , 10, e1245	13
840	Quantitative epitope analysis reveals drastic 63% reduced immuno-affinity and 60% enhanced transmissibility for SARS-CoV-2 variants.	0
839	Sex Hormones and Lung Inflammation. 2021 , 1304, 259-321	10
838	Self-Organizing, Symmetry Breaking, Isogenic Human Lung Buds on Microchips Identify Alveolar Stem Cells as Novel Targets of SARS-CoV-2.	
837	Structural determinants driving the binding process between PDZ domain of wild type human PALS1 protein and SLiM sequences of SARS-CoV E proteins. 2021 , 19, 1838-1847	3
836	Role of Sensors, Devices and Technology for Detection of COVID-19 Virus. 2021 , 293-312	
835	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. 2021 , 27, 10760296211021498	25
834	3044 Cases reveal important prognosis signatures of COVID-19 patients. 2021 , 19, 1163-1175	5
833	Effect of mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion function. 2021 ,	1
832	Protein Structure, Dynamics and Assembly: Implications for Drug Discovery. 2021 , 91-122	
831	The evolutionary making of SARS-CoV-2.	
830	Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. 2020 , 44, e20200198	1
829	Insight into the origin of SARS-CoV-2 through structural analysis of receptor recognition: a molecular simulation study.. 2021 , 11, 8718-8729	1
828	Insight into molecular characteristics of SARS-CoV-2 spike protein following D614G point mutation, a molecular dynamics study. 2021 , 1-9	10
827	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. 2021 , 12, 593223	42
826	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. 2021 , 11, e297	32
825	Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. 2021 , 19, 3133-3148	5

824	Pathophysiology and possible treatments for olfactory-gustatory disorders in patients affected by COVID-19. 2021 , 2, 100035	12
823	The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. 2021 , 48, 1763-1771	2
822	SARS-CoV-2 mutations: the biological trackway towards viral fitness. 2021 , 149, e110	17
821	SARS-CoV-2 and approaches for a testing and diagnostic strategy. 2021 , 9, 8157-8173	1
820	SARS-CoV-2 infection susceptibility influenced by ACE2 genetic polymorphisms: insights from Tehran Cardio-Metabolic Genetic Study. 2021 , 11, 1529	11
819	The SARS-CoV-2 B.1.618 variant slightly alters the spike RBD-ACE2 binding affinity and is an antibody escaping variant: a computational structural perspective.. 2021 , 11, 30132-30147	24
818	A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2. 2021 , 13,	3
817	Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. 2021 , 23, 12549-12558	3
816	Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition. 2021 , 19, 3006-3014	1
815	Endolysosomal Ca signaling in cardiovascular health and disease. 2021 , 363, 203-269	8
814	Determination of intermediate state structures in the opening pathway of SARS-CoV-2 spike using cryo-electron microscopy. 2021 , 12, 9168-9175	10
813	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. 2021 , 12, 264	41
812	Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. 2021 , ,	13
811	Interaction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations.. 2021 , 11, 3272-3279	11
810	Molecular recognition of SARS-CoV-2 spike glycoprotein: quantum chemical hot spot and epitope analyses.. 2021 , 12, 4722-4739	22
809	The immune response in bacterial and viral infectious diseases. 2021 , 3, 20	
808	Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein. 2021 , 595, 442-451	4
807	Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin. 2021 , 7, 264-272	60

806	Structure of SARS CoV2. 2021 , 11-24	1
805	Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. 2021 , 35, 231-247	10
804	An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility. 2021 , 12, 4407-4419	
803	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. 2021 , 34, 108630	123
802	Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. 2021 , 13, 1953683	8
801	Impairment of olfactory and gustatory sensations in severe acute respiratory syndrome corona virus 2 (SARS-CoV-2 virus) disease. 2021 , 10, 2153-2158	
800	Furin cleavage sites naturally occur in coronaviruses. 2020 , 50, 102115	25
799	The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment. 2021 , 15, 11779322211002168	6
798	An overview of potential inhibitors targeting non-structural proteins 3 (PL and Mac1) and 5 (3CL/M) of SARS-CoV-2. 2021 , 19, 4868-4883	11
797	Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants.. 2021 , 11, 31460-31476	
796	Harnessing the Capability of CADD Methods in the Prediction of Anti-COVID Drug Likelihood. 2021 , 269-287	
795	A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. 2021 , 69, 18-25	11
794	Limitations and Implications of Doubling Time Approach in COVID-19 Infection Spreading Study. 2021 , 137-148	
793	Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population. 2021 , 13, 1-18	4
792	SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. 2021 , 4, 129	46
791	Protein-based lateral flow assays for COVID-19 detection. 2021 , 34,	12
790	Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications. 2021 , 14,	31
789	Genetic Variation and Evolution of the 2019 Novel Coronavirus. 2021 , 24, 54-66	4

- 788 The Risk Mitigation Measures Implemented in China. **2021**, 308, 01025
- 787 CORONAVIRUSES [HOW PROTEIN INTERACTIONS CHANGED OUR PERCEPTION OF THE WORLD. **2021**, 60, 121-135
- 786 Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA. **2021**, 12, 1597-1609 17
- 785 Structures of SARS-CoV-2 RNA-Binding Proteins and Therapeutic Targets. **2021**, 64, 55-68 11
- 784 50 Years of structural immunology. **2021**, 296, 100745 3
- 783 Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. **2021**, 22, 45
- 782 A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. **2021**, 12, 542 86
- 781 A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. **2022**, 5, 1
- 780 Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces. 0
- 779 SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation. 13, 1
- 778 In silico screening of some compounds derived from the desert medicinal plant *Rhazya stricta* for the potential treatment of COVID-19. **2022**, 12, 1
- 777 A Comprehensive Review on Covid-19 Omicron (B.1.1.529) Variant. **2022**, 103372 1
- 776 Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. **2022**, 3,
- 775 Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. **2022**, 14, 1560 2
- 774 Screened α -Helix Peptide Inhibitor toward SARS-CoV-2 by Blocking a Prion-like Domain in the Receptor Binding Domain.
- 773 Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. **2022**, 12, 964
- 772 Advances in COVID-19 Vaccines and New Coronavirus Variants. 9, 0
- 771 Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder. **2022**, 14, 1432 0

770	Clinical grade ACE2 as a universal agent to block SARS-CoV -2 variants.	4
769	Trimeric Receptor Binding Domain of SARS-CoV-2 Acts as a Potent Inhibitor of ACE2 Receptor-Mediated Viral Entry. 2022 , 104716	0
768	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. 1-21	0
767	NMR Experiments Provide Insights into Ligand-Binding to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.	0
766	COVID-19 and male infertility: An overview of the disease. 2022 , 101, e29401	3
765	Influence of SARS-CoV-2 variants spike glycoprotein and RNA-dependent RNA polymerase (nsp12) mutations on remdesivir docking residues. 2022 , 24, 617-628	0
764	Pharmacological Profile of Nigella sativa Seeds in Combating COVID-19 through In-Vitro and Molecular Docking Studies. 2022 , 10, 1346	0
763	Leveraging metabolic modeling to identify functional metabolic alterations associated with COVID-19 disease severity. 2022 , 18,	0
762	A Retinol Derivative Inhibits SARS-CoV-2 Infection by Interrupting Spike-Mediated Cellular Entry.	1
761	Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates. 2022 , 10, 117	0
760	Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells.	0
759	Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. 2022 , 17, e0271066	1
758	Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. 2200060	0
757	Molecular docking and identification of G-protein-coupled receptor 120 (GPR120) agonists as SARS COVID-19 MPro inhibitors. 2022 , 20,	0
756	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. 2022 , 11, 269-297	0
755	Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis. 13,	6
754	All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes.	2
753	Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19. 2022 , 11, 2175	3

752	Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters. 2022 ,	
751	Antibody levels to SARS-CoV -2 spike protein in mothers and children from delivery to six months later.	1
750	Mechanisms of COVID-19 Pathogenesis in Diabetes.	3
749	Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2. 2022 , 17, e0271112	3
748	Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. 2022 ,	0
747	Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. 13,	
746	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. 2022 , 6, 791-805	3
745	SARS-CoV-2 and the Central Nervous System: Emerging Insights into Hemorrhage-Associated Neurological Consequences and Therapeutic Considerations. 2022 , 101687	1
744	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies.	4
743	Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein.	
742	Structural interactions of phytoconstituent(s) from cinnamon, bay leaf, oregano, and parsley with SARS-CoV -2 nucleocapsid protein: A comparative assessment for development of potential antiviral nutraceuticals.	0
741	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. 2022 , 10, 1103	0
740	The association of human leucocyte antigen (HLA) alleles with COVID-19 severity: A systematic review and meta-analysis.	0
739	SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern (VOCs) including Omicron. 1-19	0
738	Colchicine for the treatment of COVID-19: short path from theory to practice. 2022 , 71-79	
737	Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins. 2022 , 25, 104722	1
736	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. 2022 , 25, 104705	2
735	An integrated understanding of the evolutionary and structural features of the SARS-CoV-2 spike receptor binding domain (RBD). 2022 , 217, 492-505	0

- 734 Carlina oxide inhibits the interaction of SARS-CoV-2 S glycoprotein with angiotensin-converting enzyme 2. **2022**, 187, 115338 o
- 733 Coronaviruses. **2023**, 277-306
- 732 Predictive Models of within- and between-Species SARS-CoV-2 Transmissibility. **2022**, 14, 1565
- 731 The impact of ACE2 and co-factors on SARS-CoV-2 infection in colorectal cancer. **2022**, 12, o
- 730 Oral antiviral treatments for COVID-19: opportunities and challenges. 4
- 729 Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation. 1-23
- 728 The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. 1
- 727 N- glycoproteomic profiling revealing novel coronavirus therapeutic targets potentially involved in Cepharanthine intervention. **2022**, 100156 o
- 726 The Glycan-Binding Trait of the Sarbecovirus Spike N-Terminal Domain Reveals an Evolutionary Footprint. 1
- 725 A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. 13, o
- 724 QTQTN motif upstream of the furin-cleavage site plays a key role in SARS-CoV-2 infection and pathogenesis. **2022**, 119, 3
- 723 Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2. 1
- 722 Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico. 9,
- 721 Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis Complicated by Neurological Involvement in a Patient with Dermatomyositis: a Case Report and Literature Review.
- 720 Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. **2022**, 104141 o
- 719 Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. **2022**, 23, 8177 1
- 718 A Bayesian approach to infer recombination patterns in coronaviruses. **2022**, 13, 1
- 717 Design and selection of peptides to block the SARS-CoV-2 receptor binding domain by molecular docking. 13, 699-711 o

716	Net-Shaped DNA Nanostructures Designed for Rapid/Sensitive Detection and Potential Inhibition of the SARS-CoV-2 Virus.	6
715	Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures. 2022 , 12,	0
714	Determinants of Spike Infectivity, Processing and Neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. 2022 ,	6
713	Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. 2022 , 624, 122042	1
712	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. 2022 , 51, 101569	3
711	Design and finite element modeling of two-dimensional nanomechanical biosensors for SARS-CoV-2 detection. 2022 , 128, 109263	
710	Single-particle detection of native SARS-CoV-2 virions by microfluidic resistive pulse sensing. 2022 , 218, 112716	0
709	Antibody-receptor bioengineering and its implications in designing bioelectronic devices. 2022 , 218, 225-242	1
708	Stem Cells: A Promising Therapeutic Target for COVID-19. 2022 , 12, 1-27	1
707	Engineered disulfide reveals structural dynamics of locked SARS-CoV-2 spike. 2022 , 18, e1010583	0
706	Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. 2022 , 7,	1
705	Identification of SARS-CoV-2 inhibitors through phylogenetics and drug repurposing.	1
704	Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study. 2022 , 3, e36100	0
703	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. 2022 , 23, 8485	1
702	Mass Changes the Diffusion Coefficient of Particles with Ligand-Receptor Contacts in the Overdamped Limit. 2022 , 129,	0
701	Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation. 13,	
700	Convolutional Neural Network Applied to SARS-CoV-2 Sequence Classification. 2022 , 22, 5730	
699	Structural and Dynamic Insights into SARS-CoV-2 Spike-Protein/Montmorillonite Interactions. 2022 , 38, 9186-9194	

- 698 Covariance predicts conserved protein residue interactions important for the emergence and continued evolution of SARS-CoV-2 as a human pathogen. **2022**, 17, e0270276
- 697 Molecular dynamics simulations explore effects of electric field orientations on spike proteins of SARS-CoV-2 virions. **2022**, 12, 1
- 696 The role of surfactant proteins SP-A and SP-D in viral infection: a focus on COVID-19. **2022**, 21, 195-206
- 695 Association between obesity and COVID-19. **2022**, 65, 423-429
- 694 Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs. **2022**, 12, 1060 0
- 693 A potent virucidal activity of functionalized TiO₂ nanoparticles adsorbed with flavonoids against SARS-CoV-2. 0
- 692 Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines. **2022**, 2, 1
- 691 NOTCH signaling in COVID-19: a central hub controlling genes, proteins, and cells that mediate SARS-CoV-2 entry, the inflammatory response, and lung regeneration. 12, 0
- 690 Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation Studies of the Molecular Targets and Mechanisms of ChuanKeZhi in the Treatment of COVID-19. **2022**, 17, 1934578X2211169⁰
- 689 Missense mutations in spike protein of SARS-CoV-2 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor. **2022**, 10,
- 688 The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes. **2022**, 5, 1
- 687 Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis. 10, 3
- 686 Serum peptidome profiles immune response of COVID-19 Vaccine administration. 13, 0
- 685 Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. **2022**, 13, 7
- 684 Intermediates in SARS-CoV-2 spike-mediated cell entry. **2022**, 8, 2
- 683 In vitro selection of a single-strand DNA aptamer targeting the receptor-binding domain of SARS-CoV-2 spike protein. 1-14
- 682 Intensity of Humoral Immune Responses, Adverse Reactions, and Post-Vaccination Morbidity after Adenovirus Vector-Based and mRNA Anti-COVID-19 Vaccines. **2022**, 10, 1268 0
- 681 Vascular Implications of COVID-19: Role of Radiological Imaging, Artificial Intelligence, and Tissue Characterization: A Special Report. **2022**, 9, 268 1

- 680 Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. **2022**, 111299 0
- 679 A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. **2022**, 96, 2
- 678 Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. **2022**, 78, 0
- 677 Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. **2022**, 2
- 676 Anti-Spike and Neutralizing Antibodies after Two Doses of COVID-19 Sinopharm/BIBP Vaccine. **2022**, 10, 1340 2
- 675 Viral Dynamic Surveillance in COVID-19 Patients: A Cohort Study. **2022**, 2022, 1-10
- 674 Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. 1
- 673 Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study. 13, 1
- 672 Bilateral Psoas Haematoma Following Extracorporeal Membranous Oxygenation in a Patient with Severe COVID-19 (SARS CoV-2). A Rare Case Report and Literature Review..
- 671 COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. **2022**, 28, 2211-2233
- 670 Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples. **2022**, 2022, 1-7
- 669 Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2. **2022**, 167, 1931-1946 2
- 668 An improved Fuzzy based GWO algorithm for predicting the potential host receptor of COVID-19 infection. **2022**, 106050 1
- 667 In vitro high-content tissue models to address precision medicine challenges. **2022**, 101108
- 666 Phytochemical drug discovery for COVID-19 using high-resolution computational docking and machine learning assisted binder prediction. 1-21
- 665 High sensitivity detection of SARS-CoV-2 by an optofluidic hollow eccentric core fiber. **2022**, 13, 4592 1
- 664 Repurposing Drugs as Potential Therapeutics for the SARS-Cov-2 Viral Infection: Automatizing a Blind Molecular Docking High-throughput Pipeline.
- 663 A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. **2022**, 17, e0272364 0

662	Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development.	0
661	Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine.	1
660	Independent acquisition of short insertions at the RIR1 site in the spike N-terminal domain of the SARS-CoV-2 BA.2 lineage.	
659	PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. 2022 , 5,	0
658	Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China. 2022 ,	1
657	Two Years into the COVID-19 Pandemic: Lessons Learned.	4
656	Protein Design: From the Aspect of Water Solubility and Stability.	7
655	Synthesis and Biological Evaluation of Umifenovir Analogues as Anti-SARS-CoV-2 Agents. 2022 , 7,	
654	Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice. 2022 , 15,	0
653	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. 2022 , 14, 3263	1
652	Impact of high-dose vitamin C on the mortality, severity, and duration of hospital stay in COVID-19 patients: A meta-analysis. 2022 , 5,	2
651	Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise. 2022 ,	1
650	Functional profiling of Covid 19 vaccine candidate by flow virometry. 2022 ,	
649	Computational Design of Miniprotein Inhibitors Targeting SARS-CoV-2 Spike Protein.	1
648	Evaluation of SARS-CoV-2 patients with annual RT-PCR analysis results. 2022 , 13, em00804	2
647	Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India. 2022 , 10, 1312	
646	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. 2022 , 13,	0
645	Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.	

- 644 High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses. **2022**, 17, e0271359 0
- 643 Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. **2022**, 96, 1
- 642 Deciphering inhibitory mechanism of coronavirus replication through host miRNAs-RNA-dependent RNA polymerase interactome. 13, 0
- 641 Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV -2 infection.
- 640 SCORE: SARS-CoV-2 Omicron Variant RBD-Binding DNA Aptamer for Multiplexed Rapid Detection and Pseudovirus Neutralization. 1
- 639 SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition. 1
- 638 Small Molecules Targeting SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. **2022**, 7, 28779-28789 1
- 637 Identification of three conserved linear B cell epitopes on the SARS-CoV-2 spike protein. 1-38 0
- 636 Enfermedad por COVID-19 y embarazo. **2022**, 29, 47-64
- 635 Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins. **2022**, 23, 8680 0
- 634 Molecular Dynamics Simulations of Adsorption of SARS-CoV-2 Spike Protein on Polystyrene Surface. **2022**, 62, 3814-3824 4
- 633 In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective. 12, 1
- 632 Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019-2022. **2022**, 17, e0271074 3
- 631 Bioactive natural products in COVID-19 therapy. 13, 1
- 630 Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. 13, 1
- 629 Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach. **2022**, 170, 105701
- 628 Can plant-derived anti-HIV compounds be used in COVID-19 cases?. **2022**, 166, 110926 0
- 627 COVID-19 detection using X-ray images and statistical measurements. **2022**, 201, 111702

- 626 Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages. **2022**, 148, 105903
- 625 Scaled-attention: A novel fast attention mechanism for efficient modeling of protein sequences. **2022**, 609, 1098-1112
- 624 Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. **2022**, 170, 105699 1
- 623 Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. **2022**, 219, 980-997 1
- 622 Multivalent ACE2 engineering: A promising pathway for advanced coronavirus nanomedicine development. **2022**, 46, 101580 1
- 621 Charge transport properties of SARS-CoV-2 Delta variant (B.1.617.2). **2022**, 121, 656-660
- 620 Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. **2022**, 111, 109161 2
- 619 Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning. **2022**, 149, 105969 1
- 618 Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. **2022**, 111, 109128 1
- 617 Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection. **2022**, 309, 114597 0
- 616 Decoding molecular factors shaping human angiotensin converting enzyme 2 receptor usage by spike glycoprotein in lineage B beta-coronaviruses. **2022**, 1868, 166514
- 615 Epigenetic dysregulation in autophagy signaling as a driver of viral manifested oral carcinogenesis. **2022**, 1868, 166517
- 614 Ultrasensitive voltammetric detection of SARS-CoV-2 in clinical samples. **2022**, 371, 132539 2
- 613 Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. **2023**, 251, 123813 0
- 612 Production and secretion of functional SARS-CoV-2 spike protein in *Chlamydomonas reinhardtii*. 13, 2
- 611 Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. 0
- 610 Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions. 0
- 609 In-silico designing of a multi-epitope vaccine against SARS-CoV2 and studying the interaction of the vaccine with Alpha, Beta, Delta, and Omicron variants of concern. **2022**, 19, 0

608	The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection. 2022 , 154, 113625	0
607	Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants. 2022 , 627, 168-175	0
606	Genomic and epidemiologic surveillance of SARS-CoV-2 in Southern Brazil and identification of a new Omicron-L452R sublineage. 2022 , 321, 198907	0
605	Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. 2022 , 367, 110179	1
604	ZnO-chlorogenic acid nanostructured complex inhibits Covid-19 pathogenesis and increases hydroxychloroquine efficacy. 2022 , 34, 102296	1
603	Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches. 2022 , 367, 110161	2
602	Omicron variant: Current insights and future directions. 2022 , 265, 127204	6
601	Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era. 2022 , 265, 127206	0
600	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. 2022 , 4, 100054	0
599	Overexpression of estrogen receptor GPER1 and G1 treatment reduces SARS-CoV-2 infection in BEAS-2B bronchial cells. 2022 , 558, 111775	0
598	Paradigm shift from conventional processes to advanced membrane adsorption-mediated inactivation processes towards holistic management of virus A critical review. 2022 , 10, 108568	0
597	Current clinical testing approach of COVID. 2022 , 231-274	0
596	Overview and applications of map and model validation tools in the CCP-EM software suite.	0
595	The Research Progress on Diagnostic Methods for COVID-19. 2022 , 12, 8043-8049	0
594	The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021. 2022 ,	0
593	Community, Economy and COVID-19: A Primer for Lessons from Multi-Country Analyses of a Global Pandemic. 2022 , 1-30	1
592	Microorganisms as potential source of drug for SARS-CoV-2 (COVID-19). 2022 , 171-189	0
591	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. 2022 , 143-160	0

- 590 Genetics and Biological Characteristics of SARS-CoV-2. **2022**, 49-66 o
- 589 Serum Angiotensin II as a Biomarker in COVID-19. **2022**, 1-24 o
- 588 SARS-CoV-2 genome sequencing and promising druggable targets. **2022**, 3-22 1
- 587 Natural drugs for the treatment of severe acute respiratory syndrome coronaviruses infections (SARS-CoV and COVID-19). **2022**, 73-153 o
- 586 In silico investigation and identification of bioactive compounds from medicinal plants as potential inhibitors against SARS-CoV-2 cellular entry. **2022**, 355-376 o
- 585 Procalcitonin levels in COVID-19 patients in a tertiary care center. **2022**, 15, 282 o
- 584 Computationally Repurposed Natural Products Targeting SARS-CoV-2 Attachment and Entry Mechanisms. **2022**, 505-537 o
- 583 High-resolution analysis of individual spike peptide-specific CD4 + T-cell responses in vaccine recipients and COVID -19 patients. **2022**, 11, o
- 582 Biophysical and structural characterizations of the effects of mutations on the structure-activity relationships of SARS-CoV-2 spike protein. **2022**, o
- 581 Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study (Preprint). o
- 580 Antibody-mediated immunity to SARS-CoV-2 spike. **2022**, 1-69 o
- 579 COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part I. COVID-19 and Influenza. **2022**, 37, 1-9 o
- 578 Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein. 1-14 o
- 577 COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. 9, o
- 576 The Omicron Variant of the Sars-Cov-2 Virus As the Dominant Agent of a New Risk of Disease amid the COVID-19 Pandemic. **2022**, 92, 381-391 o
- 575 Potential COVID -19 Therapeutics in Clinical Trials A Brief Review. **2022**, 10, 737-742 o
- 574 Strain Variation Based on Spike Glycoprotein Gene of SARS-CoV-2 in Kuwait from 2020 to 2021. **2022**, 11, 985 o
- 573 COVID-19 And Chronic Kidney Diseases. **2022**, 181-229 o

572	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP. 2022 , 94, 12274-12279	0
571	A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. 2022 , 7,	1
570	Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. 2022 , 11, 5103	0
569	Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. 2022 , 32, 1073-1085	0
568	COVID-19 and Cardiovascular Manifestations. 2022 , 102-136	0
567	The role of B cells in COVID-19 infection and vaccination. 13,	3
566	Proteomics research of SARS-CoV-2 and COVID-19 disease. 2022 , 2, 427-445	0
565	Nanotechnology and COVID-19 Convergence: Toward New Planetary Health Interventions Against the Pandemic. 2022 , 26, 473-488	0
564	Therapeutic Potential of Myrrh, a Natural Resin, in Health Management through Modulation of Oxidative Stress, Inflammation, and Advanced Glycation End Products Formation Using In Vitro and In Silico Analysis. 2022 , 12, 9175	1
563	Circadian orchestration of host and gut microbiota in infection.	0
562	The relationship between diabetes and the severity of COVID-19.	0
561	RNA structure-altering mutations underlying positive selection on Spike protein reveal novel putative signatures to trace crossing host-species barriers in Betacoronavirus. 2022 , 19, 1019-1044	0
560	N-3 polyunsaturated fatty acids may affect the course of COVID-19. 13,	0
559	Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2. 9,	0
558	Host adaptation of codon usage in SARS-CoV-2 from mammals indicates potential natural selection and viral fitness.	1
557	Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2.	1
556	When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy.	2
555	Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2. 2022 , 11, 1035	0

554	Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. 13,	0
553	Marine Alga <i>Ulva fasciata</i> -Derived Molecules for the Potential Treatment of SARS-CoV-2: An In Silico Approach. 2022 , 20, 586	0
552	Natural furin inhibitor(s) as potent therapeutic molecule to mitigate SARS-CoV-2 infection. 1-7	0
551	In situ analysis of nanoparticle soft corona and dynamic evolution. 2022 , 13,	3
550	ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection. 2022 , 20, e3001754	4
549	Electrostatic Features for the Receptor Binding Domain of SARS-COV-2 Wildtype and Its Variants. Compass to the Severity of the Future Variants with the Charge-Rule. 2022 , 126, 6835-6852	1
548	Atomistic Simulations and Network-Based Energetic Profiling of Binding and Allostery in the SARS-CoV-2 Spike Omicron BA.1, BA.1.1, BA.2 and BA.3 Subvariant Complexes with the Host Receptor: Revealing Hidden Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Long-Range Communication with Allosteric Pockets.	0
547	Probing Mechanisms of Binding and Allostery in the SARS-CoV-2 Spike Omicron Variant Complexes with the Host Receptor: Revealing Functional Roles of the Binding Hotspots in Mediating Epistatic Effects and Communication with Allosteric Pockets. 2022 , 23, 11542	2
546	Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. 2022 ,	0
545	SARS-CoV-2 Spatiotemporal Genomic and Molecular Analysis of the First Wave of the COVID-19 Pandemic in Macaé the Brazilian Capital of Oil. 2022 , 23, 11497	0
544	Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein. 13,	0
543	Energetics of Spike Protein Opening of SARS-CoV-1 and SARS-CoV-2 and Its Variants of Concern: Implications in Host Receptor Scanning and Transmission.	0
542	Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against Omicron.	0
541	Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy. 2022 , 13, 738-751	0
540	Identification and characterization of a novel cell binding and cross-reactive region on spike protein of SARS-CoV-2. 2022 , 12,	0
539	Neurological changes post-covid-19 infection. 2022 , 10, 336-350	0
538	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.	0
537	Flap structure within receptor binding domain of SARS-CoV-2 spike periodically obstructs hACE2 Binding subdomain bearing similarities to HIV-1 protease flap. 2022 , 12,	0

536	Applications of Functional DNA Materials in Immunomodulatory Therapy.	0
535	Lung Organoids as Model to Study SARS-CoV-2 Infection. 2022 , 11, 2758	1
534	Evidence for multiple binding modes in the initial contact between SARS-CoV-2 spike S1 protein and cell surface glycans.	0
533	Thromboembolic Disease and Cardiac Thrombotic Complication in COVID-19: A Systematic Review. 2022 , 12, 889	1
532	Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. 2022 , 12,	3
531	Structure and Epitope of a Neutralizing Monoclonal Antibody that Targets the Stem Helix of β Coronaviruses.	0
530	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. 13,	1
529	Tracking mutational semantics of SARS-CoV-2 genomes. 2022 , 12,	0
528	Proteomics-based mass spectrometry profiling of SARS-CoV-2 infection from human nasopharyngeal samples.	0
527	Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors. 2022 , 12,	1
526	Designing multi-epitope based peptide vaccine targeting spike protein SARS-CoV-2 B.1.1.529 (Omicron) variant using computational approaches.	1
525	Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. 13,	0
524	Pharmacological features, health benefits and clinical implications of honokiol. 1-23	1
523	Self-assembling protein nanoparticles and virus like particles correctly display β barrel from meningococcal factor H-binding protein through genetic fusion. 2022 , 17, e0273322	2
522	Nasal swab mRNA expression profile associated with SARS-CoV-2 infection in children: Integrated RNA-Seq dataset analyses.	0
521	A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling. 2022 , 28,	0
520	Investigation of potential tea polyphenols against SARS-CoV-2 targets: A Computational approach.	0
519	MVsim is a toolset for quantifying and designing multivalent interactions. 2022 , 13,	0

- 518 A Putative long-range RNA-RNA interaction between ORF8 and Spike of SARS-CoV-2. **2022**, 17, e0260331 0
- 517 Structural perspective of the interactions of ACE2 and SARS CoV-2 Spike protein RBD. 0
- 516 Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. **2022**, 8, 1
- 515 On the Origins of Omicron Unique Spike Gene Insertion. **2022**, 10, 1509 0
- 514 Engineering recombinantly expressed lectin-based antiviral agents. 12, 0
- 513 Photobiomodulation reduces the cytokine storm syndrome associated with Covid-19 in the zebrafish model. 0
- 512 Expediting the drug discovery for ideal leads against SARS-CoV-2 via molecular docking of repurposed drugs. 1-17 0
- 511 Modeling of the thermal properties of SARS-CoV-2 S-protein. 9, 1
- 510 Utility of in silico-identified-peptides in spike-S1 domain and nucleocapsid of SARS-CoV-2 for antibody detection in COVID-19 patients and antibody production. **2022**, 12, 1
- 509 Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. **2022**, 11, 2275-2287 5
- 508 Human Caring Theory: Approach to Breastfeeding Mothers During Covid-19 Pandemia. 0
- 507 In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine. 9, 0
- 506 High-yield production in Escherichia coli and convenient purification of a candidate vaccine against SARS-CoV-2. 0
- 505 SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations. 0
- 504 Immune Evasion of SARS-CoV-2 Omicron Subvariants. **2022**, 10, 1545 0
- 503 The COVID-19 pandemic and Alzheimer disease: mutual risks and mechanisms. **2022**, 11, 2
- 502 SP-A binding to the SARS-CoV-2 spike protein using hybrid quantum and classical in silico modeling and molecular pruning by Quantum Approximate Optimization Algorithm (QAOA) Based MaxCut with ZDOCK. 13, 0
- 501 Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. **2022**, 5, 0

- 500 A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. **2022**, 20, o
- 499 Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. o
- 498 Nanobody engineering for SARS-CoV-2 neutralization and detection. o
- 497 Antioxidant, Anti-inflammatory, and Immunomodulatory Roles of Nonvitamin Antioxidants in Anti-SARS-CoV-2 Therapy. o
- 496 Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. o
- 495 Recent advances in small-molecular therapeutics for COVID-19. o
- 494 Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. **2022**, 105193 1
- 493 Mechanosensing view of SARS-CoV-2 infection by a DNA nano-assembly. **2022**, 3, 101048 o
- 492 Localized delivery of nanomedicine and antibodies for combating COVID-19. **2022**, o
- 491 Genomic surveillance of SARS-CoV-2 in Ontario, Canada reveals biases in mutational patterns between successive epochs delimited by major public health events (Preprint). o
- 490 #COVIDisAirborne: AI-enabled multiscale computational microscopy of delta SARS-CoV-2 in a respiratory aerosol. 109434202211282 o
- 489 Druggable targets and therapeutic development for COVID-19. 10, o
- 488 Longitudinal neutralization activities on authentic Omicron variant provided by 3 doses of BBIBP-CorV vaccination during one year. 2200306 o
- 487 Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. **2022**, 8, 3
- 486 Androgens role in severity and mortality rates of COVID-19. o
- 485 Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors. 1
- 484 Adaptation-Proof SARS-CoV-2 Vaccine Design. 2206055 o
- 483 Determination of soluble angiotensin-converting enzyme 2 in saliva samples and its association with nicotine. **2022**, 114443 o

482	Biparatopic nanobodies targeting the receptor binding domain efficiently neutralise SARS-CoV-2. 2022 , 105259	0
481	SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. 4,	0
480	Managing Covid-19 in patients with heart failure: current status and future prospects.	0
479	Recombinant Protein Micelles to Block Transduction by SARS-CoV-2 Pseudovirus.	1
478	Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody. 2022 , 8,	3
477	Effect of Disulfide Bridge on the Binding of SARS-CoV-2 Fusion Peptide to Cell Membrane: A Coarse-Grained Study.	1
476	Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. 2022 , 155, 113766	2
475	Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. 2022 , 150, 106129	2
474	Non-uniform aspects of the SARS-CoV-2 intraspecies evolution reopen question of its origin. 2022 , 222, 972-993	0
473	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. 2021 , 85-114	0
472	Clustering SARS-CoV-2 Variants from Raw High-Throughput Sequencing Reads Data. 2022 , 133-148	0
471	Biological effect of black phosphorus nanosheets to the interaction between SARS-CoV-2 S protein and ACE2.	0
470	CryoAI: Amortized Inference of Poses for Ab Initio Reconstruction of 3D Molecular Volumes from Real Cryo-EM Images. 2022 , 540-557	0
469	Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2. 2022 , 14, 2178	0
468	Promising on-site and rapid SARS-CoV-2 detection via antigens. 10,	0
467	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. 2022 , 41, 111496	1
466	Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations. 2022 , 14, 2259	1
465	Aspergillus-SARS-CoV-2 Coinfection: What Is Known?. 2022 , 11, 1227	0

464	Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. 2,	0
463	Negative air ions through the action of antioxidation, anti-inflammation, anti-apoptosis and angiogenesis ameliorate lipopolysaccharide induced acute lung injury and promote diabetic wound healing in rat. 2022 , 17, e0275748	0
462	Lactoferrin Binding to SARS-CoV-2 Spike Glycoprotein Blocks Pseudoviral Entry and Relieves Iron Protein Dysregulation in Several In Vitro Models. 2022 , 14, 2111	1
461	A snapshot of protein trafficking in SARS-CoV-2 infection.	1
460	SARS-CoV-2 modulates inflammatory responses of alveolar epithelial type II cells via PI3K/AKT pathway. 13,	1
459	Proviral role of human respiratory epithelial cell-derived small extracellular vesicles in SARS-CoV-2 infection. 2022 , 11,	2
458	The SARS-CoV-2 S1 Spike Protein Promotes MAPK and NF-κB Activation in Human Lung Cells and Inflammatory Cytokine Production in Human Lung and Intestinal Epithelial Cells. 2022 , 10, 1996	0
457	Spike protein mediated membrane fusion during SARS-CoV-2 infection.	0
456	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. 2022 , 10, 1751	0
455	Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 13,	1
454	A Review of Potential Therapeutic Strategies for COVID-19. 2022 , 14, 2346	1
453	Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care. 2022 , 58, 1554	0
452	Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2. 2022 , 12, 862	0
451	Variation analysis of SARS-CoV-2 complete sequences from Iran.	0
450	SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response. 13,	0
449	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. 2022 , 105465	0
448	Sensitive Detection of SARS-CoV-2 Variants Using an Electrochemical Impedance Spectroscopy Based Aptasensor. 2022 , 23, 13138	0
447	Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. 2022 , 14, 1109-1140	0

446	The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees.	0
445	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation.	0
444	SARS-CoV-2 downregulates ACE2 through lysosomal degradation.	1
443	SARS-CoV-2 Spike Protein (RBD) Subunit Adsorption at Abiotic Surfaces and Corona Formation at Polymer Particles. 2022 , 23, 12374	0
442	Molecular and Structural Analysis of Specific Mutations from Saudi Isolates of SARS-CoV-2 RNA-Dependent RNA Polymerase and their Implications on Protein Structure and Drug Binding. 2022 , 27, 6475	2
441	Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy. 13,	0
440	Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome.	0
439	Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. 2022 , 10, 1999	0
438	Antiviral drug design based on structural insights into the N-terminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein. 2022 ,	0
437	A bovine antibody possessing an ultralong complementarity-determining region CDRH3 targets a highly conserved epitope in sarbecovirus spike proteins. 2022 , 102624	0
436	Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. 2022 , 7,	2
435	Triggering type 1 diabetes post-covid: molecular mimicry?.	0
434	Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction. 2022 , 12,	0
433	Design Strategies for and Stability of mRNA-lipid Nanoparticle COVID-19 Vaccines. 2022 , 14, 4195	2
432	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.	3
431	HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection State.	1
430	High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2.	0
429	Enhanced Inactivation of Pseudoparticles Containing SARS-CoV-2 S Protein Using Magnetic Nanoparticles and an Alternating Magnetic Field.	1

428	Acute Myocardial Infarction Complicating Coronavirus Infection (Case Report). 2022 , 18, 18-23	0
427	Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b. 2022 , 105444	0
426	Irradiation of UVC LED at 277 nm inactivates coronaviruses in association to photodegradation of spike protein. 2022 , 8, e11132	0
425	Effects of a Shift of the Signal Peptide Cleavage Site in Signal Peptide Variant on the Synthesis and Secretion of SARS-CoV-2 Spike Protein. 2022 , 27, 6688	1
424	LRRC15 inhibits SARS-CoV-2 cellular entry in trans. 2022 , 20, e3001805	1
423	Omicron SARS-CoV-2 Spike-1 Protein Decreased Binding Affinity to α 7nAChR: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway An In Silico Analysis. 2022 , 2, 553-564	0
422	Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. 2202556	0
421	Cereals as a Source of Bioactive Compounds with Anti-Hypertensive Activity and Their Intake in Times of COVID-19. 2022 , 11, 3231	0
420	Cyclophilin A-mediated mitigation of coronavirus SARS-CoV -2.	1
419	Inhibition of the Cell Uptake of Delta and Omicron SARS-CoV-2 Pseudoviruses by N-Acetylcysteine Irrespective of the Oxidoreductive Environment. 2022 , 11, 3313	0
418	Stability and expression of SARS-CoV-2 spike-protein mutations.	0
417	Glycosylation in SARS-CoV-2 Variants: A path to Infection and Recovery. 2022 , 115335	2
416	SARS-CoV-2-on-Chip for Long COVID Management. 2022 , 12, 890	1
415	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections.	0
414	State-of-the-art tools to elucidate the therapeutic potential of TAT-peptide (TP) conjugated repurposing drug against SARS-CoV-2 spike glycoproteins. 2022 , 29,	0
413	Zebrafish models of COVID-19.	2
412	Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants. 2022 , 106262	1
411	SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. 2022 , 5,	3

- 410 LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19. **2022**, 25, 105314 2
- 409 Effect of the Graphene Nanosheet on Functions of the Spike Protein in Open and Closed States: Comparison between SARS-CoV-2 Wild Type and the Omicron Variant. 0
- 408 Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants. 0
- 407 Temporal Transcriptome Analysis of SARS-CoV-2-Infected Lung and Spleen in Human ACE2-Transgenic Mice. **2022**, 0
- 406 Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination. **2022**, 133, 102918 0
- 405 OCT and OCTA evaluation of vascular and morphological structures in the retina in recovered pediatric patients with COVID-19. **2022**, 40, 103157 0
- 404 Novel coronavirus mutations: Vaccine development and challenges. **2022**, 173, 105828 1
- 403 Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides. **2022**, 208, 105445 1
- 402 Peptides, lipopeptides, and severe acute respiratory syndrome coronavirus-2. **2023**, 381-422 0
- 401 Hypothesis of the role of magnesium upon COVID-19 infection and disease onset. **2022**, 0
- 400 mRNA vaccines for COVID-19. **2023**, 611-624 0
- 399 ??????????????????????????????. **2022**, 125, 1440-1445 0
- 398 Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in macaques. **2022**, 1
- 397 Active Ingredients of Reduning Injections Maintain High Potency against SARS-CoV-2 Variants. 1
- 396 In silico strategies to identify protein-protein interaction modulator in cell-to-cell transmission of SARS CoV2. 0
- 395 SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. 4
- 394 Proteolysis and Deficiency of H^+ -Proteinase Inhibitor in SARS-CoV-2 Infection. **2022**, 16, 271-291 0
- 393 Antigenic mapping reveals sites of vulnerability on H^+ CoV spike protein. **2022**, 5, 0

392	Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases. 2022 , 22,	2
391	In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2. 2022 , 27, 7572	1
390	Efficient SARS-CoV-2 detection utilizing chitin-immobilized nanobodies synthesized in <i>Ustilago maydis</i> .	0
389	Evolutionary Signals in Coronaviral Structural Proteins Suggest Possible Complex Mechanisms of Post-Translational Regulation in SARS-CoV-2 Virus. 2022 , 14, 2469	0
388	Antiviral effects of phytochemicals against severe acute respiratory syndrome coronavirus 2 and their mechanisms of action: A review.	2
387	A Review on Structural, Non-structural, and Accessory Proteins of SARS-CoV-2: Highlighting Drug Target Sites. 2022 , 152302	0
386	Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise. 2022 , 100281	1
385	E-Cigarette Vapour Increases ACE2 and TMPRSS2 Expression in a Flavour- and Nicotine-Dependent Manner. 2022 , 19, 14955	0
384	Inactivation of SARS-CoV-2 and Other Human Coronaviruses Aided by Photocatalytic One-Dimensional Titania Nanotube Films as a Self-Disinfecting Surface. 2022 , 14, 50463-50474	0
383	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS.	0
382	Fusion assays for screening of fusion inhibitors targeting SARS-CoV-2 entry and syncytia formation. 13,	1
381	COVID-19 and Diarrhea: Putative Mechanisms and Management. 2022 ,	1
380	Coding Complete Genome Sequence of the SARS-CoV-2 Virus Strain, Variant B.1.1, Sampled from Kazakhstan.	0
379	Understanding Molecular Actors of SARS-CoV-2 Virulence to Tackle COVID-19 Outbreak. 2022 , 11, 3597	0
378	Detection of COVID-19: A Smartphone-Based Machine-Learning-Assisted ECL Immunoassay Approach with the Ability of RT-PCR CT Value Prediction.	0
377	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. 13,	1
376	SARS-CoV -2 spike protein capture by peptide functionalized networks.	0
375	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.	0

- 374 Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. **2022**, 19, 1
- 373 Electron cryotomography of SARS-CoV-2 virions reveals cylinder-shaped particles with a double layer RNP assembly. **2022**, 5, 1
- 372 Micro-second Time-resolved X-ray Single-molecule Internal Motions of SARS-CoV-2 Spike Variants. 0
- 371 Involvement of sialoglycans in SARS-COV -2 infection: opportunities and challenges for glyco-based inhibitors. 0
- 370 Immunosenescence and ACE2 protein expression: Association with SARS-CoV-2 in older adults. **2022**, 6, 008-017 0
- 369 The Impact of Coronavirus Disease 2019 on Maternal and Fetal Wellbeing in New Mexico. **2022**, 12, 2856 0
- 368 Longitudinal Antibody Titer, Avidity, and Neutralizing Responses after SARS-CoV-2 Infection. **2022**, e11676 0
- 367 Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix. **2022**, 0
- 366 A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant. 1
- 365 Conformational stability of SARS-CoV-2 glycoprotein spike variants. **2023**, 26, 105696 0
- 364 Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. **2023**, 26, 105783 0
- 363 Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. **2023**, 26, 105726 0
- 362 Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants. **2023**, 299, 102732 0
- 361 Functionalized biological metal-organic framework with nanosized coronal structure and hierarchical wrapping pattern for enhanced targeting therapy. **2023**, 456, 140963 1
- 360 Role of nanotechnology in diagnosis and disease control with a focus on COVID-19 and future perspectives. **2023**, 269-283 0
- 359 Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. **2023**, 226, 780-792 0
- 358 Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster. **2023**, 209, 105507 0
- 357 Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. **2023**, 208, 115370 0

- 356 COVID-19 infection and metabolic comorbidities: Mitigating role of nutritional sufficiency and drug Nutraceutical combinations of vitamin D. **2023**, 31, 200179 ○
- 355 Modelling SARS-CoV-2 spike-protein mutation effects on ACE2 binding. **2023**, 119, 108379 ○
- 354 Expression, purification, and study on the efficiency of a new potent recombinant scFv antibody against the SARS-CoV-2 spike RBD in E. coli BL21. **2023**, 203, 106210 ○
- 353 Discovery of novel thioquinazoline-N-aryl-acetamide/N-arylacetohydrazide hybrids as anti-SARS-CoV-2 agents: Synthesis, in vitro biological evaluation, and molecular docking studies. **2023**, 1276, 134690 1
- 352 Large-Scale Production and Business Plan for Novel Corona Vaccine. **2022**, 303-323 ○
- 351 Identifying Large Scale Conformational Changes in Proteins Through Distance Maps and Convolutional Networks. **2022**, 56-67 ○
- 350 Investigation of COVID-19 Serology in a Tertiary Care Center. ○
- 349 Marginal SARS-CoV-2 Spike Protein Increases Interferon and Balances Cytokine Gene Expression. **2022**, 4, 9-22 ○
- 348 Endosomes, receptors, and viruses. **2022**, 378, 845-845 ○
- 347 An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. 13, ○
- 346 An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. 13, 1
- 345 Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants. **2022**, 23, 14796 1
- 344 The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case. 2201853 ○
- 343 In Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19. **2022**, 2, 1731-1747 ○
- 342 Structural evolution of Delta lineage of SARS-CoV-2. **2022**, ○
- 341 Parent Acceptance toward Inactivated COVID-19 Vaccination in Children with Acute Lymphoblastic Leukemia: The Power of Oncologist and Alliance. **2022**, 10, 2016 ○
- 340 No Smell, No Taste Dealing With a Senseless Phase of the Pandemic. **2022**, 57, 309-316 ○
- 339 Pea eggplant (*Solanum torvum* Swartz) is a source of plant food polyphenols with SARS-CoV inhibiting potential. 10, e14168 ○

- 338 COVID-19 Antibodies as Predictor of Severe Dengue among Hospitalized Children with Dengue Illness in the Post-third-wave Period of COVID-19 Infection in India. **2022**, 70, 45-48 ○
- 337 Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning. **2022**, 8, 1
- 336 The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic. 1
- 335 A Systematic Review and Quality Evaluation of Studies on Long-Term Sequelae of COVID-19. **2022**, 10, 2364 ○
- 334 Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. **2022**, 10, 2035 ○
- 333 Secondary conformation of MERS-CoV, SARS-CoV and SARS-CoV-2 Spike Proteins revealed by Infrared Vibrational Spectroscopy. ○
- 332 Effect of Uncomplicated Diabetes Mellitus on Acute Respiratory Distress Syndrome Among COVID-19 Patients in Aseer Region, Saudi Arabia. **2022**, ○
- 331 Plant lectins as versatile tools to fight coronavirus outbreaks. ○
- 330 SARS-CoV-2 in brief: from virus to prevention. 1
- 329 Pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska. **2022**, 12, ○
- 328 RNA G-quadruplex forming regions from SARS-2, SARS-1 and MERS coronaviruses. 10, ○
- 327 Computer Simulation of the Interaction between SARS-CoV-2 Spike Protein and the Surface of Coinage Metals. **2022**, 38, 14673-14685 1
- 326 The free fatty acid binding pocket is a conserved hallmark in pathogenic β -Coronavirus spike proteins from SARS-CoV to Omicron. **2022**, 8, ○
- 325 DYNAMICS OF CLINICAL SYMPTOMS AND SECRETORY IMMUNOGLOBULIN A IN COVID-19 CONVALESCENT PATIENTS. ○
- 324 From acute SARS-CoV-2 infection to pulmonary hypertension. 13, 1
- 323 The SARS-CoV-2 spike protein binds and modulates estrogen receptors. **2022**, 8, 2
- 322 Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid. **2023**, 24, 20 ○
- 321 Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. **2022**, 11, 1786 ○

- 320 Electron microscopy holdings of the Protein Data Bank: the impact of the resolution revolution, new validation tools, and implications for the future. o
- 319 Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. o
- 318 Tracing the First Days of the SARS-CoV-2 Pandemic in Greece and the Role of the First Imported Group of Travelers. **2022**, 10, o
- 317 Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. 1
- 316 A Glimpse on the Evolution of RNA Viruses: Implications and Lessons from SARS-CoV-2. **2023**, 15, 1 o
- 315 Model exploration for discovering COVID-19 targeted traditional Chinese medicine. **2022**, 8, e12333 o
- 314 Structural plasticity of omicron BA.5 and BA.2.75 for enhanced ACE-dependent entry into cells. 1-12 o
- 313 Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants. o
- 312 Liver injury in COVID-19: Holds ferritinophagy-mediated ferroptosis accountable. 10, 13148-13156 o
- 311 Epidemiological Features and Phylogeny of SARS-CoV-2 Circulating in the Southeast Asia in Early Pandemic. 139-147 o
- 310 Precise Detection on Cell-Cell Fusion by a Facile Molecular Beacon-Based Method. **2022**, 94, 17334-17340 o
- 309 Outcome of COVID-19 infection in people with diabetes mellitus or obesity in the primary care setting in Catalonia, Spain: A retrospective cohort study of the initial three waves. **2022**, o
- 308 Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection. **2022**, 147144 o
- 307 Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases. **2022**, 12, 1226 o
- 306 In Vitro and In Silico Studies for the Identification of Potent Metabolites of Some High-Altitude Medicinal Plants from Nepal Inhibiting SARS-CoV-2 Spike Protein. **2022**, 27, 8957 o
- 305 SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia. o
- 304 Donor selection for adoptive cell therapy with CD45RA⁺ memory T cells for COVID-19 patients, and dexamethasone and interleukin-15 effect on the phenotype, proliferation and interferon gamma release. **2022**, o
- 303 High-Yield Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope and Receptor Binding Domain of SARS-CoV-2 in Plants Using Viral Vectors. **2022**, 23, 15684 o

- 302 Identification and mechanistic basis of non-ACE2 blocking neutralizing antibodies from COVID-19 patients with deep RNA sequencing and molecular dynamics simulations. 9, 0
- 301 Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics. **2022**, 167928 0
- 300 Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2. **2022**, 14, 2825 0
- 299 Single-virus tracking reveals variant SARS-CoV-2 spike proteins induce ACE2-independent membrane interactions. **2022**, 8, 1
- 298 Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective. 0
- 297 Discovery of novel spike/ACE2 inhibitory macrocycles using in silico reinforcement learning. 2, 0
- 296 Plant production of high affinity nanobodies that block SARS-CoV-2 spike protein binding with its receptor, human angiotensin converting enzyme. 10, 0
- 295 Diabetes mellitus and hypertension as risk factors of acute kidney injury induced by COVID-19: A systematic review and meta-analysis. **2022**, 35, 1-9 0
- 294 In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein. **2022**, 14, 2823 0
- 293 Gastrointestinal microbiota: A predictor of COVID-19 severity?. 28, 6328-6344 2
- 292 Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?. 0
- 291 Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses. 13, 0
- 290 Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. **2023**, 11, 30 1
- 289 Mutational Patterns Observed in SARS-CoV-2 Genomes Sampled From Successive Epochs Delineated by Major Public Health Events in Ontario, Canada: Genomic Surveillance Study. **2022**, 3, e42243 0
- 288 Molecular Epidemiology of the Norwegian SARS-CoV-2 Delta Lineage AY.63. **2022**, 14, 2734 0
- 287 A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility. 13, 1
- 286 HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies. **2022**, 12, 2089 0
- 285 Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement. **2022**, 2022, 1-12 0

- 284 COVID-19: Some Pathophysiological and Endocrine Aspects. **2022**, 15, 112-117 o
- 283 Pineapple Lectin AcMJRL Binds SARS-CoV-2 Spike Protein in a Carbohydrate-Dependent Fashion**. o
- 282 Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. **2022**, 612, 748-757 3
- 281 SARS-CoV-2 Spike Protein Mutation at Cysteine-488 Impairs Its Golgi Localization and Intracellular S1/S2 Processing. **2022**, 23, 15834 o
- 280 High-Efficiency Adsorption of SARS-CoV-2 Spike 1 Protein by Plasma-Modified Porous Polymers. **2022**, 12, 12628 o
- 279 Evaluation of S- and M-Proteins Expressed in Escherichia coli and HEK Cells for Serological Detection of Antibodies in Response to SARS-CoV-2 Infections and mRNA-Based Vaccinations. **2022**, 11, 1515 o
- 278 Corona virus disease 2019-associated liver injury in cold regions. **2022**, 2, 193-199 o
- 277 Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods. **2022**, 18, e1010230 o
- 276 Prophylaxis and Remediation for Future Pandemic Pathogens(Lessons from a Post-COVID World). **2022**, 10, 2407 o
- 275 An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody responsein vivo. o
- 274 Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses (SARS-CoV -1 and SARS-CoV -2). o
- 273 Three on Three: Universal and High-Affinity Molecular Recognition of the Symmetric Homotrimeric Spike Protein of SARS-CoV-2 with a Symmetric Homotrimeric Aptamer. 1
- 272 Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level. **2022**, 13, o
- 271 The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBDACE2 Binding Interface. **2022**, 27, 8938 o
- 270 The D614G mutation redirects SARS-CoV-2 spike to lysosomes and suppresses deleterious traits of the furin cleavage site insertion mutation. **2022**, 8, o
- 269 Dressing bacteria with a hybrid immunoactive nanosurface to elicit dual anticancer and antiviral immunity. 2210949 o
- 268 COVID Vaccination for Children: A Literature Review. **2022**, 4, 13-17 o
- 267 COVID-19 inhibits spermatogenesis in the testes by inducing cellular senescence. 13, o

- 266 Integration of LC-MS, NMR and molecular docking for profiling of bioactive diterpenes from *Euphorbia mauritanica* L. with in-vitro anti-SARS-CoV-2 activity. o
- 265 Current topic of vascular function in hypertension. o
- 264 Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches. 13, o
- 263 Proinflammatory and Thrombotic Manifestations and the Therapeutic Options of COVID-19. **2023**, 49-78 o
- 262 Expression of angiotensin converting enzyme 2 mRNA in different SARS-CoV-2 infection states and times. 1-7 o
- 261 Structural Analysis and Epitope Prediction of S2 Domain of SARS-CoV-2, Conservation Analysis Among Major Variants. o
- 260 COVID-19 and Autoimmunity. **2022**, 57-84 o
- 259 Receptor-binding domain of SARS-CoV-2 is a functional α -integrin agonist. **2023**, 102922 o
- 258 Rethinking the Role of the Renin-Angiotensin System in the Pandemic Era of SARS-CoV-2. **2023**, 10, 14 o
- 257 SARS-CoV-2 N protein mediates intercellular nucleic acid dispersion, a feature reduced in Omicron. **2023**, 105995 1
- 256 Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2. **2023**, 11, 160 o
- 255 Functionalized Fullerene for Inhibition of SARS-CoV-2 Variants. 2206154 o
- 254 Bioinformatic analysis of the S protein of human respiratory coronavirus. **2023**, 107704 o
- 253 Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. **2023**, 9, e12667 o
- 252 *Artemisia argyi* potentially prevents the infections with SARS-CoV-2 variants. o
- 251 Critical review of conformational B-cell epitope prediction methods. 1
- 250 The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. **2023**, 20, 2
- 249 A novel mRNA vaccine, SYS6006, against SARS-CoV-2. 13, o

- 248 Production and characterisation of a SARSCoV-2 S-protein RBD homodimer with increased avidity for specific antibodies. o
- 247 Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature. **2023**, o
- 246 The SARS-CoV-2 Spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice. o
- 245 Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots. o
- 244 Liver dysfunction-related COVID-19: A narrative review. 11, 5-17 o
- 243 Cross-species transmission, evolution and zoonotic potential of coronaviruses. 12, o
- 242 Editorial: SARS-CoV-2 variants, B lymphocytes, and autoreactivity. 13, o
- 241 Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease. o
- 240 Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay. 10, o
- 239 Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein. **2023**, 42, 111964 o
- 238 Humoral immunity for durable control of SARS-CoV-2 and its variants. **2023**, 43, o
- 237 Recombinant SARS-CoV-2 Spike Protein and its Receptor Binding Domain stimulate release of different pro-inflammatory mediators via activation of distinct receptors on human microglia cells. 1
- 236 A Comprehensive Perspective of Traditional Arabic or Islamic Medicinal Plants as an Adjuvant Therapy against COVID-19. **2023**, 103561 o
- 235 A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. **2023**, 95, 1
- 234 Comparative docking studies of drugs and phytocompounds for emerging variants of SARS-CoV-2. **2023**, 13, o
- 233 Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. **2023**, 133, o
- 232 S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. **2023**, 11, 193 o
- 231 Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2. **2023**, 208, 115401 o

- 230 QM/MM study of N501 involved intermolecular interaction between SARS-CoV-2 receptor binding domain and antibody of human origin. **2023**, 102, 107810 ○
- 229 Fingerprinting trimeric SARS-CoV-2 RBD by capillary isoelectric focusing with whole-column imaging detection. **2023**, 663, 115034 ○
- 228 Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. **2023**, 315, 121374 ○
- 227 Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. **2023**, 37, e00780 ○
- 226 Current status and future challenges in extraction, purification and identification of Cepharanthine (a potential drug against COVID-19). **2023**, 309, 123038 ○
- 225 Molecular Docking Analysis on the Antiviral Effects of Curcumin on SARS-CoV-2. ○
- 224 On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. **2023**, 15, 70 ○
- 223 Computational Analysis of Receptor-Binding Domains of SARS-CoV-2 to Reveal the Mechanism of Immune Escape. **2022**, ○
- 222 Efficacy and safety of Qi and Blood Tonic Chinese Medicines in the treatment of COVID-19: A protocol for systematic review and meta-analysis. **2022**, 101, e32136 ○
- 221 Structural proteins of SARS-CoV-2. **2023**, 13, 45-52 ○
- 220 Aptamer-Linked Photonic Crystal Assay for High-Throughput Screening of HIV and SARS-CoV-2. ○
- 219 Multiformin-Type Azaphilones Prevent SARS-CoV-2 Binding to ACE2 Receptor. **2023**, 12, 83 ○
- 218 Entropic Overcompensation of the N501Y Mutation on SARS-CoV-2 S Binding to ACE2. ○
- 217 COVID-19: Epidemiology, Virology, Transmission, and Prevention. **2022**, 2, 1-5 ○
- 216 Emerging Dominant SARS-CoV-2 Variants. **2023**, 63, 335-342 5
- 215 COVID-19: Virology. **2023**, 22-33 ○
- 214 Defining neutralization and allostery by antibodies against COVID-19 variants. ○
- 213 SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2. **2023**, 15, 360 ○

- 212 False-Positive Human Immunodeficiency Virus Results in COVID-19 Patients. **2023**, o
- 211 Use of the D614G Mutation of the SARS-CoV-2 Spike Protein as a Biophysical Model to Explain Coulomb's Law Function. **2023**, 14, 103-110 o
- 210 Genomics, metagenomics, and pan-genomics approaches in COVID-19. **2023**, 23-39 o
- 209 Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus. 13, o
- 208 Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface. **2023**, 13, o
- 207 Machine learning in computational modelling of membrane protein sequences and structures: From methodologies to applications. **2023**, 21, 1205-1226 o
- 206 Covid-19 and cancer: impact on diagnosis, care and therapy. **2023**, 127-144 o
- 205 Revealing the Molecular Interactions between Human ACE2 and the Receptor Binding Domain of the SARS-CoV-2 Wild-Type, Alpha and Delta Variants. **2023**, 24, 2517 1
- 204 A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19). **2023**, 11, 295 o
- 203 Epitope-directed anti-SARS-CoV -2 scFv engineered against the key spike protein region could block membrane fusion. o
- 202 Tutorial review on the processing and performance of fabrics with antipathogenic inorganic agents. o
- 201 SARS-CoV-2 spike and ACE2 entanglement-like binding. **2023**, 5, o
- 200 Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. o
- 199 Immunological and metabolic characteristics of the Omicron variants infection. **2023**, 8, 1
- 198 Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. 13, o
- 197 Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. **2023**, 10, 148 o
- 196 Structural features of sensory two component systems: a synthetic biology perspective. **2023**, 480, 127-140 o
- 195 The OM-85 bacterial lysate: A new tool against SARS-CoV-2?. 18, o

- 194 Molecular interaction modeling of carbon nanotubes and fullerene toward prioritized targets of SARS-CoV-2 by computer-aided screening and docking studies. **2023**, 157-179 ○
- 193 COVID-19 and pediatrics phylogeny, pathology, and pathogenesis of SARS-CoV-2. **2023**, 23-40 ○
- 192 CoV2-TCR: A web server for screening TCR CDR3 from TCR immune repertoire of COVID-19 patients and their recognized SARS-CoV-2 epitopes. **2023**, 21, 1362-1371 ○
- 191 Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. **2023**, 15, 451 ○
- 190 Epigenetic features, methods, and implementations associated with COVID-19. **2023**, 161-175 ○
- 189 Expanding and Improving Nanobody Repertoires Using a Yeast Display Method: Targeting SARS-CoV-2. **2023**, 102954 ○
- 188 Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice. **2023**, 11, 314 ○
- 187 Coarse-Grained Modeling of the SARS-CoV-2 Spike Glycoprotein by Physics-Informed Machine Learning. **2023**, 11, 24 ○
- 186 SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. **2023**, 13, 559 1
- 185 Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: Pharmacophore-based virtual screening, molecular docking, molecular dynamics and binding free energy studies. **2023**, 375, 121345 ○
- 184 The inhibitory activity of Ruxolitinib against COVID-19 major protease enzyme and SARS CoV-2 spike glycoprotein: A molecular docking study. **2023**, 8, 1-9 ○
- 183 The role of spike protein entry inhibitors in the treatment of mild-to-moderate covid-19 in nonhospitalized patients. **2022**, 9, 52-59 ○
- 182 Therapeutic Potential of Nitric Oxide in the Management of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS). **2023**, 249-258 ○
- 181 Cellular mechanisms of transcriptional regulation of human cell lines exposed to cadmium-based quantum dots. **2023**, 10, 1177-1189 ○
- 180 The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study. **2023**, 71, ○
- 179 Oral manifestations of COVID-19 correlated to medical and drug history, a survey on infected medical doctors.. ○
- 178 A review of the SARS-CoV-2 viral genome mutation and its effects. **2023**, 10, 1-4 ○
- 177 SARS-CoV-2 Angiotensin Converting Enzyme 2 (ACE2) Receptor Expression and Its Effects on COVID-19 Epidemiology in Children. ○

- 176 A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19. **2023**, 20, 351-364 ○
- 175 Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. **2023**, 29, ○
- 174 A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine. **2023**, 41, 2615-2629 ○
- 173 Evolutionary aspects of mutation in functional motif and post-translational modifications in SARS-CoV-2 3CLpro (Mpro): an in-silico study. ○
- 172 In silico targeting of SARS-CoV-2 spike receptor-binding domain from different variants with chaga mushroom terpenoids. 1-9 ○
- 171 Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. 14, ○
- 170 Density estimation of SARS-CoV2 spike proteins using super pixels segmentation technique. **2023**, 138, 110210 ○
- 169 Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants. **2023**, 213, 105587 ○
- 168 The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. **2023**, 213, 105590 ○
- 167 Burgeoning therapeutic strategies to curb the contemporary surging viral infections. **2023**, 179, 106088 ○
- 166 Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. **2023**, 152, 1-21 ○
- 165 Insight into the mechanisms of coronaviruses evading host innate immunity. **2023**, 1869, 166671 ○
- 164 Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2. **2023**, 660, 43-49 ○
- 163 Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis. **2023**, 65, 108143 ○
- 162 Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy. **2023**, 79, 111-121 1
- 161 Spatial shifting of COVID-19 clusters and disease association with environmental parameters in India: A time series analysis. **2023**, 222, 115288 ○
- 160 Omicron mutations increase interdomain interactions and reduce epitope exposure in the SARS-CoV-2 spike. **2023**, 26, 105981 ○
- 159 Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2. **2023**, 211, 105541 ○

- 158 Enhancing neutralizing antibodies against receptor binding domain of SARS-CoV-2 by a safe natural adjuvant system. **2023**, 326, 199047 ○
- 157 Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents. **2023**, 31, 370-382 ○
- 156 Bilemizde Uygulanan Biontech ve Sinovac Aşıları Karşı Gelici Bir Antikor Yanıtına Neden Olmuştur. **2023**, 1, 1-10 ○
- 155 New emerging pandemic: head and neck manifestations. **2023**, 113, ○
- 154 Evaluating COVID-19 Sequence Data Using Nearest-Neighbors Based Network Model. **2022**, ○
- 153 Informative Initialization and Kernel Selection Improves t-SNE for Biological Sequences. **2022**, ○
- 152 Eptopedia: identifying molecular mimicry between pathogens and known immune epitopes. **2023**, 9, 100023 ○
- 151 The Role of the Plasminogen/Plasmin System in Inflammation of the Oral Cavity. **2023**, 12, 445 ○
- 150 SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction. **2023**, 6, ○
- 149 Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets. **2023**, 18, 247-268 ○
- 148 Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. **2023**, 33, 188-202 ○
- 147 Adsorption and Inactivation of SARS-CoV-2 on the Surface of Anatase TiO₂(101). **2023**, 15, 8770-8782 ○
- 146 Reads2Vec: Efficient Embedding of Raw High-Throughput Sequencing Reads Data. ○
- 145 On the Sensitivity and Affinity of Gold, Silver, and Platinum Surfaces against the SARS-CoV-2 Virus: A Comparative Computational Study. **2023**, 63, 1276-1292 ○
- 144 Impact of COVID-19 on the cardiovascular health of women: a review by the Italian Society of Cardiology Working Group on Gender cardiovascular diseases. **2023**, 24, e15-e23 ○
- 143 Identification of natural compounds as SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation. 13, ○
- 142 LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein. **2023**, 21, e3001959 1
- 141 A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. **2023**, 11, 371 ○

- 140 Computational design of candidate multi-epitope vaccine against SARS-CoV-2 targeting structural (S and N) and non-structural (NSP3 and NSP12) proteins. 1-20 o
- 139 Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants. **2023**, 11, 374 o
- 138 A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. **2023**, 24, 3255 o
- 137 Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein. **2023**, 21, 1550-1556 o
- 136 In Silico Discovery of Small Molecule Modulators Targeting the Achilles' Heel of SARS-CoV-2 Spike Protein. o
- 135 The Role of Cluster of Differentiation 39 (CD39) and Purinergic Signaling Pathway in Viral Infections. **2023**, 12, 279 o
- 134 SpikeScope: A Tool for Analyzing Structural Diversity in Experimental Structures of the SARS-CoV-2 Spike Glycoprotein. **2023**, 63, 1087-1092 o
- 133 Performance characteristics of the boson rapid SARS-CoV-2 antigen test card vs RT-PCR: Cross-reactivity and emerging variants. **2023**, 9, e13642 o
- 132 SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection. **2023**, 26, 106175 o
- 131 Immunoinformatics Study: Multi-Epitope Based Vaccine Design from SARS-CoV-2 Spike Glycoprotein. **2023**, 11, 399 o
- 130 Altered microRNA Transcriptome in Cultured Human Airway Cells upon Infection with SARS-CoV-2. **2023**, 15, 496 o
- 129 Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. **2023**, 11, 517 o
- 128 Transferrin Receptor Protein 1 Cooperates with mGluR2 To Mediate the Internalization of Rabies Virus and SARS-CoV-2. **2023**, 97, o
- 127 Inhibitors of the RBD-ACE-2 Found among a Wide Range of Dyes by the Immunoassay Method. **2023**, 11, 135 o
- 126 Impact of COVID-19 on Cardiovascular Disease. **2023**, 15, 508 o
- 125 Understanding the SARS-CoV-2 Virus Neutralizing Antibody Response: Lessons to Be Learned from HIV and Respiratory Syncytial Virus. **2023**, 15, 504 o
- 124 Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. **2023**, 18, e0281689 o
- 123 Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization. **2023**, 31, 1136-1158 o

- 122 Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody. **2023**, 24, 3774 ○
- 121 Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. **2023**, 8, ○
- 120 Membrane cholesterol regulates the oligomerization and fusogenicity of SARS-CoV fusion peptide: implications in viral entry. **2023**, 25, 7815-7824 ○
- 119 Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions. **2023**, 97, ○
- 118 Targeted genotyping of COVID-19 patients reveals a signature of complement C3 and factor B coding SNPs associated with severe infection. **2023**, 228, 152351 1
- 117 How the Competition for Cysteine May Promote Infection of SARS-CoV-2 by Triggering Oxidative Stress. **2023**, 12, 483 ○
- 116 Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology. **2023**, 11, 442 ○
- 115 Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2. **2023**, 127, 1704-1714 ○
- 114 Permethrin as a Potential Furin Inhibitor through a Novel Non-Competitive Allosteric Inhibition. **2023**, 28, 1883 ○
- 113 SARS-CoV-2 Variant-Specific mRNA Vaccine: Pros and Cons. ○
- 112 O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern. **2023**, 9, 393-404 ○
- 111 Protease allergens as initiators/ regulators of allergic inflammation. ○
- 110 Micronutrient perspective on COVID-19: Umbrella review and reanalysis of meta-analyses. 1-19 ○
- 109 SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial. **2023**, 57, 101832 ○
- 108 Origin and evolution of SARS-CoV-2. **2023**, 138, 1 ○
- 107 RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2. **2023**, 15, 555 ○
- 106 Molecular Dynamics Simulation, QSAR, DFT, Molecular Docking, ADMET, and Synthesis of Ethyl 3-((5-Bromopyridin-2-yl)Imino)Butanoate Analogues as Potential Inhibitors of SARS-CoV-2. 1-19 ○
- 105 Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps. **2023**, 31, 253-264.e6 ○

- 104 Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. 14, o
- 103 Analysis of 3.5 million SARS-CoV-2 sequences reveals unique mutational trends with consistent nucleotide and codon frequencies. **2023**, 20, o
- 102 SARS-CoV-2 spike proteins react with Au and Si, are electrically conductive and denature at 3 $\times 10^8$ V m⁻¹: a surface bonding and a single-protein circuit study. **2023**, 14, 3428-3440 o
- 101 Rapidly Adaptable Multiplexed Yeast Surface Display Serological Assay for Immune Escape Screening of SARS-CoV-2 Variants. o
- 100 SARS-CoV-2 S Glycoprotein Stabilization Strategies. **2023**, 15, 558 o
- 99 Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity. **2023**, 24, 4068 o
- 98 Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. **2023**, 26, 106256 o
- 97 Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. **2023**, 11, 524 o
- 96 Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. 14, o
- 95 Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants. **2023**, 15, 611 1
- 94 Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401 o
- 93 Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. **2023**, 11, 509 o
- 92 Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals. **2023**, 19, e1010652 o
- 91 Trends in Electroanalytical Assays for COVID-19 Diagnosis. **2023**, 1-20 o
- 90 Current status in cellular-based therapies for prevention and treatment of COVID-19. 1-25 o
- 89 Global landscape of SARS-CoV-2 mutations and conserved regions. **2023**, 21, o
- 88 SARS-CoV-2 pandemics: An update of CRISPR in diagnosis and host-virus interaction studies. **2023**, o
- 87 The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. **2022**, 9, 17-32 o

- 86 Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. **2023**, 11, 545 ○
- 85 COVID-19 Biogenesis and Intracellular Transport. **2023**, 24, 4523 2
- 84 Infections of the cardiovascular system. **2023**, 255-326 ○
- 83 Using PyMOL to Understand Why COVID-19 Vaccines Save Lives. **2023**, 100, 1351-1356 ○
- 82 SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. **2023**, 15, 639 ○
- 81 Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides. **2023**, 212, 105571 ○
- 80 Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery Genetics Alliance Perspective. **2023**, 66, 3664-3702 ○
- 79 The Coming of Age of Nucleic Acid Vaccines during COVID-19. ○
- 78 Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. **2023**, 133, ○
- 77 CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. **2023**, 161, 117000 ○
- 76 The renin-angiotensin system in the eye. **2023**, 419-447 ○
- 75 Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers : Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. ○
- 74 Cerebrovascular Manifestations of SARS-CoV-2: A Comprehensive Review. **2023**, 25, 71-92 ○
- 73 Variants of SARS-CoV-2: Influences on the Vaccines Effectiveness and Possible Strategies to Overcome Their Consequences. **2023**, 59, 507 ○
- 72 Two sides of the same coin: the N-terminal and the receptor-binding domains of SARS-CoV-2 Spike. **2023**, 18, 75-78 ○
- 71 Understanding COVID-19 in children: immune determinants and post-infection conditions. ○
- 70 TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer. ○
- 69 Exploration of potent antiviral phytomedicines from Lauraceae family plants against SARS-CoV-2 RNA-dependent RNA polymerase. 1-21 ○

- 68 Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. **2023**, 55, 471-483 ○
- 67 Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview. **2023**, 28, 2470 ○
- 66 SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. **2023**, 8, ○
- 65 Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. **2023**, 14, ○
- 64 Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2. **2023**, 95, ○
- 63 Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. 14, ○
- 62 Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. ○
- 61 A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and Omicron. **2023**, 11, 916 ○
- 60 Emerging COVID waste and its impact on the aquatic environment in India. **2023**, 101-126 ○
- 59 Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. **2023**, 21, 2339-2351 ○
- 58 Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. 12, ○
- 57 Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing. **2023**, 13, ○
- 56 Serum Angiotensin II as a Biomarker in COVID-19. **2023**, 917-940 ○
- 55 Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages : Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes. ○
- 54 Reviews of drug candidates for COVID-19. 36, 219-226 ○
- 53 Many Roles of Carbohydrates: A Computational Spotlight on the Coronavirus S Protein Binding. ○
- 52 Regulation of Epithelial Sodium Transport by SARS-CoV-2 Is Closely Related with Fibrinolytic System-Associated Proteins. **2023**, 13, 578 ○
- 51 Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. **2023**, 14, ○

- 50 Modeling of SARS-CoV-2 Virus Proteins: Implications on Its Proteome. **2023**, 265-299 ○
- 49 Molecular modeling and simulations of some antiviral drugs, benzyloquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition. **2023**, 34, 101459 ○
- 48 Photobiomodulation Reduces the Cytokine Storm Syndrome Associated with COVID-19 in the Zebrafish Model. **2023**, 24, 6104 ○
- 47 Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. **2023**, 18, e0283473 ○
- 46 Comparison and monitoring of antibody response in convalescent and healthy vaccinated individuals against RBD and PCS of SARS-CoV-2 spike protein. 1-8 ○
- 45 Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants. **2023**, 14, ○
- 44 Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. **2023**, 24, 6253 ○
- 43 Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. **2023**, 17, 7017-7034 ○
- 42 Heparan sulfate promotes ACE2 super-cluster assembly to enhance SARS-CoV-2-associated syncytium formation. ○
- 41 Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. **2023**, 15, 856 ○
- 40 Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID -19. ○
- 39 MAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity. **2023**, 42, 112310 ○
- 38 SARS-CoV-2 Receptors and Their Involvement in Cell Infection. **2023**, 17, 1-11 ○
- 37 Qualitative assessment of the risk of SARS-CoV-2 to human health through food exposures to deer in the UK. ○
- 36 More than a key: The pathological roles of SARS-CoV-2 spike protein in COVID-19 related cardiac injury. **2023**, ○
- 35 Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. 1-12 ○
- 34 Molecular Modeling of Viral Type I Fusion Proteins: Inhibitors of Influenza Virus Hemagglutinin and the Spike Protein of Coronavirus. **2023**, 15, 902 ○
- 33 Biomimetic SARS-CoV-2 Spike Protein Nanoparticles. ○

- 32 Uncovering the Role of N-Glycan Occupancy on the Cooperative Assembly of Spike and Angiotensin Converting Enzyme 2 Complexes: Insights from Glycoengineering and Native Mass Spectrometry. **2023**, 145, 8021-8032 ○
- 31 All-atom simulations of the trimeric spike protein of SARS-CoV-2 in aqueous medium: Nature of interactions, conformational stability and free energy diagrams for conformational transition of the protein. ○
- 30 Antibody Response to the SARS-CoV-2 Spike and Nucleocapsid Proteins in Patients with Different COVID-19 Clinical Profiles. **2023**, 15, 898 ○
- 29 Pan-Cancer Analysis of the COVID-19 Causal Gene SLC6A20. **2023**, 8, 13153-13161 ○
- 28 Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. **2023**, ○
- 27 Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers: Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. **2023**, 24, 6642 ○
- 26 Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants. **2023**, 6, ○
- 25 Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. **2023**, 9, ○
- 24 Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses. ○
- 23 Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. **2023**, 19, e1011206 ○
- 22 Surfactin-like lipopeptides from *Bacillus clausii* efficiently bind to spike glycoprotein of SARS-CoV-2. 1-12 ○
- 21 Emergency Protective Measures and Strategies of COVID-19: From Lifestyle to Traditional Chinese Medicine. **2023**, 100089 ○
- 20 Well-Defined Heparin Mimetics Can Inhibit Binding of the Trimeric Spike of SARS-CoV-2 in a Length-Dependent Manner. ○
- 19 SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. **2024**, 24-51 ○
- 18 SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx. **2023**, 4, 101346 ○
- 17 Prospecting native and analogous peptides with anti-SARS-CoV-2 potential derived from the trypsin inhibitor purified from tamarind seeds. **2023**, 16, 104886 ○
- 16 High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2. **2023**, 9, ○
- 15 Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021. **2023**, 111, 105434 ○

- 14 SARS-CoV-2 spike ectodomain targets $\alpha 7$ nicotinic acetylcholine receptors. **2023**, 104707 ○
- 13 Detection of IgA and IgG Antibodies against the Structural Proteins of SARS-CoV-2 in Breast Milk and Serum Samples Derived from Breastfeeding Mothers. **2023**, 15, 966 ○
- 12 A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. **2023**, 14, ○
- 11 Potential beneficial effects of functional components of edible plants on COVID-19: Based on their anti-inflammatory and inhibitory effect on SARS-CoV-2. **2023**, 2, 44-59 ○
- 10 Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. **2023**, e15587 ○
- 9 Long COVID: pathophysiological factors and abnormalities of coagulation. **2023**, ○
- 8 A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. **2023**, 19, e1011298 ○
- 7 Chewable tablet with herbal extracts and propolis arrests Wuhan and Omicron variants of SARS-CoV-2 virus. **2023**, 105544 ○
- 6 Organotypic human lung bud microarrays identify BMP-dependent SARS-CoV-2 infection in lung cells. **2023**, ○
- 5 Successive Waves of the COVID-19 Pandemic Had an Increasing Impact on Chronic Cardiovascular Patients in a Western Region of Romania. **2023**, 11, 1183 ○
- 4 Nebulizer spray delivery of phytopharmaceutical nanosuspension via oral and nasal route. **2023**, 437-457 ○
- 3 Crystallographic and biophysical analysis of the fusion core from SARS-CoV-2 spike protein. ○
- 2 Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice. **2023**, 116, 154858 ○
- 1 Association of SARS-CoV-2 Nucleocapsid Protein Mutations with Patient Demographic and Clinical Characteristics during the Delta and Omicron Waves. **2023**, 11, 1288 ○